false Q3 0000890394 --12-31 Unlimited Unlimited http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602Member true true P4Y P3Y P4Y P3Y P7Y10M20D P11M23D P3Y10M20D P3Y8M26D P1Y11M12D P7Y10M6D 1.57 15.00 25.60 144.00 410.0 1.57 14.99 25.59 143.99 409.99 924.00 924.00 2023-01-31 2023-10-31 0000890394 2022-01-01 2022-09-30 xbrli:shares 0000890394 2022-11-04 iso4217:USD 0000890394 2022-09-30 0000890394 2021-12-31 0000890394 prso:SeriesASpecialVotingPreferredStockMember 2022-09-30 0000890394 prso:SeriesASpecialVotingPreferredStockMember 2021-12-31 iso4217:USD xbrli:shares 0000890394 2021-01-01 2021-12-31 0000890394 us-gaap:ProductMember 2022-07-01 2022-09-30 0000890394 us-gaap:ProductMember 2021-07-01 2021-09-30 0000890394 us-gaap:ProductMember 2022-01-01 2022-09-30 0000890394 us-gaap:ProductMember 2021-01-01 2021-09-30 0000890394 prso:RoyaltyAndOtherMember 2022-07-01 2022-09-30 0000890394 prso:RoyaltyAndOtherMember 2021-07-01 2021-09-30 0000890394 prso:RoyaltyAndOtherMember 2022-01-01 2022-09-30 0000890394 prso:RoyaltyAndOtherMember 2021-01-01 2021-09-30 0000890394 2022-07-01 2022-09-30 0000890394 2021-07-01 2021-09-30 0000890394 2021-01-01 2021-09-30 0000890394 us-gaap:CommonStockMember 2021-12-31 0000890394 prso:ExchangeableStockMember 2021-12-31 0000890394 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000890394 us-gaap:RetainedEarningsMember 2021-12-31 0000890394 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000890394 prso:ExchangeableStockMember 2022-01-01 2022-03-31 0000890394 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000890394 2022-01-01 2022-03-31 0000890394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000890394 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000890394 us-gaap:CommonStockMember 2022-03-31 0000890394 prso:ExchangeableStockMember 2022-03-31 0000890394 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000890394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000890394 us-gaap:RetainedEarningsMember 2022-03-31 0000890394 2022-03-31 0000890394 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000890394 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000890394 2022-04-01 2022-06-30 0000890394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0000890394 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000890394 us-gaap:CommonStockMember 2022-06-30 0000890394 prso:ExchangeableStockMember 2022-06-30 0000890394 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000890394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000890394 us-gaap:RetainedEarningsMember 2022-06-30 0000890394 2022-06-30 0000890394 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000890394 prso:ExchangeableStockMember 2022-07-01 2022-09-30 0000890394 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000890394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0000890394 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000890394 us-gaap:CommonStockMember 2022-09-30 0000890394 prso:ExchangeableStockMember 2022-09-30 0000890394 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000890394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0000890394 us-gaap:RetainedEarningsMember 2022-09-30 0000890394 us-gaap:CommonStockMember 2020-12-31 0000890394 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000890394 us-gaap:RetainedEarningsMember 2020-12-31 0000890394 2020-12-31 0000890394 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000890394 2021-01-01 2021-03-31 0000890394 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000890394 us-gaap:CommonStockMember 2021-03-31 0000890394 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000890394 us-gaap:RetainedEarningsMember 2021-03-31 0000890394 2021-03-31 0000890394 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000890394 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000890394 2021-04-01 2021-06-30 0000890394 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000890394 us-gaap:CommonStockMember 2021-06-30 0000890394 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000890394 us-gaap:RetainedEarningsMember 2021-06-30 0000890394 2021-06-30 0000890394 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000890394 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000890394 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000890394 us-gaap:CommonStockMember 2021-09-30 0000890394 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000890394 us-gaap:RetainedEarningsMember 2021-09-30 0000890394 2021-09-30 xbrli:pure 0000890394 prso:ScientificResearchAndExperimentalDevelopmentMember 2022-01-01 2022-09-30 0000890394 srt:MinimumMember 2022-01-01 2022-09-30 0000890394 srt:MaximumMember 2022-01-01 2022-09-30 0000890394 us-gaap:DevelopedTechnologyRightsMember 2022-09-30 0000890394 us-gaap:CustomerRelationshipsMember 2022-09-30 0000890394 us-gaap:OtherIntangibleAssetsMember 2022-09-30 0000890394 us-gaap:DevelopedTechnologyRightsMember 2021-12-31 0000890394 us-gaap:CustomerRelationshipsMember 2021-12-31 0000890394 us-gaap:OtherIntangibleAssetsMember 2021-12-31 0000890394 us-gaap:DevelopedTechnologyRightsMember srt:MinimumMember 2022-01-01 2022-09-30 0000890394 us-gaap:DevelopedTechnologyRightsMember 2022-07-01 2022-09-30 0000890394 us-gaap:DevelopedTechnologyRightsMember 2022-01-01 2022-09-30 0000890394 us-gaap:CustomerRelationshipsMember 2022-01-01 2022-09-30 0000890394 us-gaap:CustomerRelationshipsMember 2022-07-01 2022-09-30 0000890394 2019-01-01 2019-12-31 0000890394 prso:EscrowSharesExchangeableSharesMember 2022-01-01 2022-09-30 0000890394 prso:EscrowSharesCommonStockMember 2022-01-01 2022-09-30 0000890394 prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-09-30 0000890394 prso:EmployeeAndDirectorsStockOptionsMember 2021-01-01 2021-09-30 0000890394 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0000890394 us-gaap:ConvertibleDebtSecuritiesMember 2021-01-01 2021-09-30 0000890394 prso:CommonStockWarrantsMember 2022-01-01 2022-09-30 0000890394 prso:CommonStockWarrantsMember 2021-01-01 2021-09-30 0000890394 us-gaap:CommonStockMember prso:PerasoTechMember 2022-01-01 2022-09-30 0000890394 us-gaap:CommonStockMember prso:PerasoTechMember prso:FormerSecurityHoldersMember 2022-09-30 0000890394 2021-12-17 0000890394 prso:PerasoSharesMember 2021-12-17 0000890394 prso:EscrowSharesMember 2021-12-17 utr:D 0000890394 2021-12-16 2021-12-17 0000890394 us-gaap:CommonStockMember prso:PerasoTechMember 2022-09-30 0000890394 us-gaap:CommonStockMember prso:PerasoTechMember 2021-12-31 0000890394 us-gaap:CommonStockMember prso:PerasoTechMember 2021-01-01 2021-12-31 0000890394 us-gaap:WarrantMember prso:PerasoTechMember 2021-01-01 2021-12-31 0000890394 prso:ShareBasedAwardsMember prso:PerasoTechMember 2021-01-01 2021-12-31 0000890394 prso:PerasoTechMember 2021-12-31 0000890394 prso:PrecombinationServiceShareBasedAwardsMember prso:PerasoTechMember 2021-01-01 2021-12-31 0000890394 prso:PerasoTechMember 2021-01-01 2021-12-31 0000890394 us-gaap:CashAndCashEquivalentsMember 2022-09-30 0000890394 us-gaap:ShortTermInvestmentsMember 2022-09-30 0000890394 us-gaap:CashAndCashEquivalentsMember 2021-12-31 0000890394 us-gaap:ShortTermInvestmentsMember 2021-12-31 0000890394 prso:LongTermInvestmentsMember 2021-12-31 0000890394 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000890394 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000890394 us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000890394 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000890394 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000890394 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000890394 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000890394 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0000890394 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2021-12-31 0000890394 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2021-12-31 0000890394 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember 2021-12-31 0000890394 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2022-01-01 2022-03-31 0000890394 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2022-01-01 2022-09-30 0000890394 srt:ScenarioPreviouslyReportedMember 2022-01-01 2022-03-31 0000890394 srt:RestatementAdjustmentMember 2022-01-01 2022-03-31 0000890394 stpr:CA 2022-01-01 2022-09-30 0000890394 prso:WaterlooCanadaMember 2022-01-01 2022-09-30 0000890394 prso:TorontoCanadaMember 2022-01-01 2022-09-30 0000890394 2022-04-13 0000890394 stpr:CA-ON 2022-05-26 0000890394 2022-04-13 2022-04-13 0000890394 stpr:CA-ON 2022-05-26 2022-05-26 0000890394 2022-03-01 prso:Segment 0000890394 srt:NorthAmericaMember 2022-07-01 2022-09-30 0000890394 srt:NorthAmericaMember 2021-07-01 2021-09-30 0000890394 srt:NorthAmericaMember 2022-01-01 2022-09-30 0000890394 srt:NorthAmericaMember 2021-01-01 2021-09-30 0000890394 country:HK 2022-07-01 2022-09-30 0000890394 country:HK 2021-07-01 2021-09-30 0000890394 country:HK 2022-01-01 2022-09-30 0000890394 country:HK 2021-01-01 2021-09-30 0000890394 country:TW 2022-07-01 2022-09-30 0000890394 country:TW 2021-07-01 2021-09-30 0000890394 country:TW 2022-01-01 2022-09-30 0000890394 country:TW 2021-01-01 2021-09-30 0000890394 country:JP 2022-07-01 2022-09-30 0000890394 country:JP 2022-01-01 2022-09-30 0000890394 prso:RestOfWorldMember 2022-07-01 2022-09-30 0000890394 prso:RestOfWorldMember 2021-07-01 2021-09-30 0000890394 prso:RestOfWorldMember 2022-01-01 2022-09-30 0000890394 prso:RestOfWorldMember 2021-01-01 2021-09-30 0000890394 prso:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000890394 prso:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000890394 prso:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000890394 prso:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000890394 prso:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000890394 prso:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000890394 prso:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000890394 prso:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000890394 prso:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000890394 prso:CustomerDMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000890394 prso:CustomerEMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000890394 prso:CustomerEMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000890394 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember prso:MajorCustomersMember 2022-01-01 2022-09-30 0000890394 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember prso:MajorCustomersMember 2021-01-01 2021-12-31 prso:Customer 0000890394 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember prso:MajorCustomersMember 2022-09-30 0000890394 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember prso:MajorCustomersMember 2021-12-31 0000890394 prso:EquityIncentivePlan2010Member 2022-01-01 2022-09-30 0000890394 prso:StockIncentivePlan2019Member 2022-09-30 0000890394 prso:StockIncentivePlan2019Member 2021-11-30 0000890394 prso:StockIncentivePlan2019Member prso:EmployeeAndDirectorsStockOptionsMember 2022-09-30 0000890394 prso:StockIncentivePlan2019Member prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-09-30 0000890394 prso:StockIncentivePlan2019Member prso:EmployeeAndDirectorsStockOptionsMember srt:MinimumMember 2022-01-01 2022-09-30 0000890394 prso:StockIncentivePlan2019Member prso:EmployeeAndDirectorsStockOptionsMember srt:MaximumMember 2022-01-01 2022-09-30 0000890394 prso:NewEmployeesMember 2022-09-30 0000890394 prso:EmployeeAndDirectorsStockOptionsMember 2022-09-30 0000890394 prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-09-30 0000890394 prso:EmployeeAndDirectorsStockOptionsMember 2021-01-01 2021-09-30 0000890394 us-gaap:RestrictedStockUnitsRSUMember 2022-09-30 0000890394 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0000890394 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember 2021-12-31 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember 2022-03-31 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember us-gaap:RestrictedStockUnitsRSUMember 2022-04-01 2022-06-30 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember 2022-06-30 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember 2022-09-30 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember 2022-01-01 2022-03-31 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember 2022-04-01 2022-06-30 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember 2022-07-01 2022-09-30 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember us-gaap:RestrictedStockUnitsRSUMember 2022-03-31 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember us-gaap:RestrictedStockUnitsRSUMember 2022-06-30 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember us-gaap:RestrictedStockUnitsRSUMember 2022-09-30 0000890394 prso:RangeOfExercisePriceOneMember prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-09-30 0000890394 prso:RangeOfExercisePriceTwoMember prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-09-30 0000890394 prso:RangeOfExercisePriceThreeMember prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-09-30 0000890394 prso:RangeOfExercisePriceFourMember prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-09-30 0000890394 prso:RangeOfExercisePriceFiveMember prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-09-30 0000890394 prso:RangeOfExercisePriceSixMember prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-09-30 0000890394 prso:RangeOfExercisePriceOneMember prso:EmployeeAndDirectorsStockOptionsMember 2022-09-30 0000890394 prso:RangeOfExercisePriceTwoMember prso:EmployeeAndDirectorsStockOptionsMember 2022-09-30 0000890394 prso:RangeOfExercisePriceThreeMember prso:EmployeeAndDirectorsStockOptionsMember 2022-09-30 0000890394 prso:RangeOfExercisePriceFourMember prso:EmployeeAndDirectorsStockOptionsMember 2022-09-30 0000890394 prso:RangeOfExercisePriceFiveMember prso:EmployeeAndDirectorsStockOptionsMember 2022-09-30 0000890394 prso:RangeOfExercisePriceSixMember prso:EmployeeAndDirectorsStockOptionsMember 2022-09-30 0000890394 prso:CommonStockOneMember 2022-09-30 0000890394 prso:CommonStockTwoMember 2022-09-30 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2021-02-05 2021-02-05 iso4217:CAD 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2021-03-05 2021-03-05 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2021-09-17 2021-09-17 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2022-01-01 2022-09-30 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2022-09-30 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2021-08-01 2021-08-31 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2021-12-16 2021-12-16 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2021-07-01 2021-09-30 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2021-01-01 2021-09-30 0000890394 us-gaap:ConvertibleDebtMember 2021-07-01 2021-09-30 0000890394 us-gaap:ConvertibleDebtMember 2021-01-01 2021-09-30 0000890394 prso:LoanFacilitiesMember 2021-07-01 2021-09-30 0000890394 prso:LoanFacilitiesMember 2021-01-01 2021-09-30 0000890394 prso:ConsultantMember 2022-01-01 2022-09-30 0000890394 prso:ConsultantMember 2021-01-01 2021-09-30 0000890394 prso:EmployedFamilyMemberMember 2022-01-01 2022-09-30 0000890394 prso:EmployedFamilyMemberMember 2021-01-01 2021-09-30 0000890394 prso:TechnologyLicenseAndPatentAssignmentAgreementMember prso:IntelCorporationMember 2022-08-05 2022-08-05 0000890394 prso:TechnologyLicenseAndPatentAssignmentAgreementMember prso:IntelCorporationMember 2022-07-01 2022-09-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark one)

| ☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2022

OR

| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 000-32929

PERASO INC.

(Exact name of registrant as specified in its charter)

Delaware |  | 77-0291941
(State or other jurisdiction |  | (I.R.S. Employer
of Incorporation or organization) |  | Identification Number)

2309 Bering Drive

San Jose, California 95131

(Address of principal executive office and zip code)

(408) 418-7500

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading symbol(s) | Name of each exchange on which registered
Common Stock, par value $0.001 per share | PRSO | The Nasdaq Stock Market, LLC

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to filing requirements for the past 90 days. Yes ☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer | ☐ |  | Accelerated filer | ☐
Non-accelerated filer | ☒ |  | Smaller reporting company | ☒
Emerging growth company | ☐ |  |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of outstanding shares of the registrant’s exchangeable shares, no par value, was 9,111,801 as of November 4, 2022.

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was 12,768,987 as of November 4, 2022.

PERASO INC.

FORM 10-Q

September 30, 2022

PART I — | FINANCIAL INFORMATION | 3
Item 1. | Financial Statements (Unaudited): | 3
| Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021 | 3
| Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2022 and 2021 | 4
| Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the three a nd nine months ended Sept ember 30, 2022 and 2021 | 5
| Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2022 and 2021 | 6
| Notes to Condensed Consolidated Financial Statements | 7
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 26
Item 4. | Controls and Procedures | 34
PART II — | OTHER INFORMATION | 34
Item 1. | Legal Proceedings | 34
Item 1A. | Risk Factors | 34
Item 6. | Exhibits | 36
| Signatures | 37

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

PERASO INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except par value)

|  | September 30, |  |  | December 31, |
|  | 2022 |  |  | 2021 |
|  | (unaudited) |  |  |  |  |
ASSETS |  |  |  |  |  |  |  |
Current assets |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 2,852 |  |  | $ | 5,893 |
Short-term investments |  |  | 1,071 |  |  |  | 9,267 |
Accounts receivable, net |  |  | 1,636 |  |  |  | 2,436 |
Inventories |  |  | 5,271 |  |  |  | 3,824 |
Tax credits and receivables |  |  | 1,076 |  |  |  | 1,099 |
Deferred cost of net revenue |  |  | 600 |  |  |  | — |
Prepaid expenses and other |  |  | 918 |  |  |  | 1,159 |
Total current assets |  |  | 13,424 |  |  |  | 23,678 |
Long-term investments |  |  | — |  |  |  | 2,928 |
Property and equipment, net |  |  | 2,058 |  |  |  | 2,349 |
Intangible assets, net |  |  | 6,803 |  |  |  | 8,355 |
Goodwill |  |  | 9,946 |  |  |  | 9,946 |
Right-of-use lease asset, net |  |  | 1,181 |  |  |  | 617 |
Other |  |  | 129 |  |  |  | 78 |
Total assets |  | $ | 33,541 |  |  | $ | 47,951 |
LIABILITIES AND STOCKHOLDERS’ EQUITY |  |  |  |  |  |  |  |
Current liabilities |  |  |  |  |  |  |  |
Accounts payable |  | $ | 1,744 |  |  | $ | 1,937 |
Accrued expenses and other |  |  | 1,867 |  |  |  | 2,903 |
Deferred revenue |  |  | 219 |  |  |  | 375 |
Short-term lease liability |  |  | 633 |  |  |  | 379 |
Total current liabilities |  |  | 4,463 |  |  |  | 5,594 |
Long-term lease liability |  |  | 554 |  |  |  | 288 |
Total liabilities |  |  | 5,017 |  |  |  | 5,882 |
Commitments and contingencies (Note 6) |  |  |  |  |  |  |  |
Stockholders’ equity |  |  |  |  |  |  |  |
Preferred stock, $0.01 par value; 20,000 shares authorized |  |  | — |  |  |  | — |
Series A special voting preferred stock, $0.01 par value; one share authorized; and one share issued and outstanding at September 30, 2022 and December 31, 2021, respectively |  |  | — |  |  |  | — |
Common stock, $0.001 par value; 120,000 shares authorized; 12,757 shares and 12,284 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively |  |  | 13 |  |  |  | 12 |
Exchangeable shares, no par value; unlimited shares authorized; 9,112 shares and 9,295 shares outstanding at September 30, 2022 and December 31, 2021, respectively |  |  | — |  |  |  | — |
Additional paid-in capital |  |  | 163,551 |  |  |  | 159,256 |
Accumulated other comprehensive loss |  |  | (36 | ) |  |  | — |
Accumulated deficit |  |  | (135,004 | ) |  |  | (117,199 | )
Total stockholders’ equity |  |  | 28,524 |  |  |  | 42,069 |
Total liabilities and stockholders’ equity |  | $ | 33,541 |  |  | $ | 47,951 |

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

PERASO INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(In thousands, except per share data)

|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 30, |  |  | September 30, |
|  | 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
Net revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product |  | $ | 3,060 |  |  | $ | 1,389 |  |  | $ | 10,384 |  |  | $ | 3,016 |
Royalty and other |  |  | 234 |  |  |  | 629 |  |  |  | 597 |  |  |  | 800 |
Total net revenue |  |  | 3,294 |  |  |  | 2,018 |  |  |  | 10,981 |  |  |  | 3,816 |
Cost of net revenue |  |  | 2,000 |  |  |  | 919 |  |  |  | 6,747 |  |  |  | 1,973 |
Gross profit |  |  | 1,294 |  |  |  | 1,099 |  |  |  | 4,234 |  |  |  | 1,843 |
Operating expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  | 4,509 |  |  |  | 2,696 |  |  |  | 15,636 |  |  |  | 8,375 |
Selling, general and administrative |  |  | 3,353 |  |  |  | 1,746 |  |  |  | 8,938 |  |  |  | 4,852 |
Gain on license and asset sale |  |  | (2,557 | ) |  |  | — |  |  |  | (2,557 | ) |  |  | — |
Total operating expenses |  |  | 5,305 |  |  |  | 4,442 |  |  |  | 22,017 |  |  |  | 13,227 |
Loss from operations |  |  | (4,011 | ) |  |  | (3,343 | ) |  |  | (17,783 | ) |  |  | (11,384 | )
Interest expense |  |  | (5 | ) |  |  | (870 | ) |  |  | (11 | ) |  |  | (2,170 | )
Other expense, net |  |  | 8 |  |  |  | 392 |  |  |  | (11 | ) |  |  | 147 |
Net loss |  | $ | (4,008 | ) |  | $ | (3,821 | ) |  | $ | (17,805 | ) |  | $ | (13,407 | )
Other comprehensive loss, net of tax: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net unrealized gain (loss) on available-for-sale securities |  |  | 5 |  |  |  | — |  |  |  | (36 | ) |  |  | — |
Comprehensive loss |  | $ | (4,003 | ) |  | $ | (3,821 | ) |  | $ | (17,841 | ) |  | $ | (13,407 | )
Net loss per share |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic and diluted |  | $ | (0.20 | ) |  | $ | (0.73 | ) |  | $ | (0.89 | ) |  | $ | (2.55 | )
Shares used in computing net loss per share |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic and diluted |  |  | 20,039 |  |  |  | 5,258 |  |  |  | 19,950 |  |  |  | 5,250 |

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

PERASO INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

(Unaudited)

(In thousands)

|  | Series A Special Voting |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Additional |  |  | Accumulated Other |  |  |  |  |  |  |  |  |
|  | Common Stock |  |  | Common Stock |  |  | Exchangeable Shares |  |  | Paid-In |  |  | Comprehensive |  |  | Accumulated |  |  |  |  |
|  | Shares |  |  | Amount |  |  | Shares |  |  | Amount |  |  | Shares |  |  | Amount |  |  | Capital |  |  | Loss |  |  | Deficit |  |  | Total |
Balance as of December 31, 2021 |  |  | — |  |  | $ | — |  |  |  | 12,284 |  |  | $ | 12 |  |  |  | 9,295 |  |  | $ | — |  |  | $ | 159,256 |  |  | $ | — |  |  | $ | (117,199 | ) |  | $ | 42,069 |
Exchange of exchangeable shares |  |  | — |  |  |  | — |  |  |  | 100 |  |  |  | — |  |  |  | (100 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Issuance of common stock under stock plan, net |  |  | — |  |  |  | — |  |  |  | 9 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (9 | ) |  |  | — |  |  |  | — |  |  |  | (9 | )
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1,171 |  |  |  | — |  |  |  | — |  |  |  | 1,171 |
Unrealized loss on available-for-sale securities |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (37 | ) |  |  | — |  |  |  | (37 | )
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (6,754 | ) |  |  | (6,754 | )
Balance as of March 31, 2022 |  |  | — |  |  |  | — |  |  |  | 12,393 |  |  |  | 12 |  |  |  | 9,195 |  |  |  | — |  |  |  | 160,418 |  |  |  | (37 | ) |  |  | (123,953 | ) |  |  | 36,440 |
Issuance of common stock under stock plan, net |  |  | — |  |  |  | — |  |  |  | 244 |  |  |  | 1 |  |  |  | — |  |  |  | — |  |  |  | (51 | ) |  |  | — |  |  |  | — |  |  |  | (50 | )
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1,738 |  |  |  | — |  |  |  | — |  |  |  | 1,738 |
Unrealized loss on available-for-sale securities |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (4 | ) |  |  | — |  |  |  | (4 | )
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (7,043 | ) |  |  | (7,043 | )
Balance as of June 30, 2022 |  |  | — |  |  |  | — |  |  |  | 12,637 |  |  |  | 13 |  |  |  | 9,195 |  |  |  | — |  |  |  | 162,105 |  |  |  | (41 | ) |  |  | (130,996 | ) |  |  | 31,081 |
Exchange of exchangeable shares |  |  | — |  |  |  | — |  |  |  | 83 |  |  |  | — |  |  |  | (83 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Issuance of common stock under stock plan, net |  |  | — |  |  |  | — |  |  |  | 37 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (2 | ) |  |  | — |  |  |  | — |  |  |  | (2 | )
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1,448 |  |  |  | — |  |  |  | — |  |  |  | 1,448 |
Unrealized gain on available-for-sale securities |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 5 |  |  |  | — |  |  |  | 5 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (4,008 | ) |  |  | (4,008 | )
Balance as of September 30, 2022 |  |  | — |  |  | $ | — |  |  |  | 12,757 |  |  | $ | 13 |  |  |  | 9,112 |  |  | $ | — |  |  | $ | 163,551 |  |  | $ | (36 | ) |  | $ | (135,004 | ) |  | $ | 28,524 |
|  | Series A Special Voting |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Additional |  |  | Accumulated Other |  |  |  |  |  |  |  |  |
|  | Common Stock |  |  | Common Stock |  |  | Exchangeable Shares |  |  | Paid-In |  |  | Comprehensive |  |  | Accumulated |  |  |  |  |
|  | Shares |  |  | Amount |  |  | Shares |  |  | Amount |  |  | Shares |  |  | Amount |  |  | Capital |  |  | Loss |  |  | Deficit |  |  | Total |
Balance as of December 31, 2020 |  |  | — |  |  | $ | — |  |  |  | 5,241 |  |  | $ | 5 |  |  |  | — |  |  | $ | — |  |  | $ | 102,361 |  |  | $ | — |  |  | $ | (106,287 | ) |  | $ | (3,921 | )
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1,177 |  |  |  | — |  |  |  | — |  |  |  | 1,177 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (4,157 | ) |  |  | (4,157 | )
Balance as of March 31, 2021 |  |  | — |  |  |  | — |  |  |  | 5,241 |  |  |  | 5 |  |  |  | — |  |  |  | — |  |  |  | 103,538 |  |  |  | — |  |  |  | (110,444 | ) |  |  | (6,901 | )
Issuance of common stock under stock plan, net |  |  | — |  |  |  | — |  |  |  | 16 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 30 |  |  |  | — |  |  |  | — |  |  |  | 30 |
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1,137 |  |  |  | — |  |  |  | — |  |  |  | 1,137 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (5,430 | ) |  |  | (5,430 | )
Balance as of June 30, 2021 |  |  | — |  |  |  | — |  |  |  | 5,257 |  |  |  | 5 |  |  |  | — |  |  |  | — |  |  |  | 104,705 |  |  |  | — |  |  |  | (115,874 | ) |  |  | (11,164 | )
Issuance of common stock under stock plan, net |  |  | — |  |  |  | — |  |  |  | 452 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1 |  |  |  | — |  |  |  | — |  |  |  | 1 |
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1,148 |  |  |  | — |  |  |  | — |  |  |  | 1,148 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (3,821 | ) |  |  | (3,821 | )
Balance as of September 30, 2021 |  |  | — |  |  | $ | — |  |  |  | 5,709 |  |  | $ | 5 |  |  |  | — |  |  | $ | — |  |  | $ | 105,854 |  |  | $ | — |  |  | $ | (119,695 | ) |  | $ | (13,836 | )

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

PERASO INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

|  | Nine Months Ended |
|  | September 30, |
|  | 2022 |  |  | 2021 |
Cash flows from operating activities: |  |  |  |  |  |  |  |
Net loss |  | $ | (17,805 | ) |  | $ | (13,407 | )
Adjustments to reconcile net loss to net cash used in operating activities: |  |  |  |  |  |  |  |
Depreciation and amortization |  |  | 2,289 |  |  |  | 783 |
Stock-based compensation |  |  | 4,357 |  |  |  | 3,461 |
Allowance for doubtful accounts |  |  | 683 |  |  |  | — |
Change in fair value of warrant liability |  |  | — |  |  |  | (113 | )
Amortization of debt discount |  |  | — |  |  |  | 1,540 |
Accrued interest expense |  |  | 4 |  |  |  | 661 |
Amortization of lease right-of-use assets |  |  | 418 |  |  |  | 182 |
Change in operating lease liabilities |  |  | (462 | ) |  |  | (177 | )
Other |  |  | 199 |  |  |  | 26 |
Changes in assets and liabilities: |  |  |  |  |  |  |  |
Accounts receivable |  |  | 117 |  |  |  | (16 | )
Inventories |  |  | (1,447 | ) |  |  | (756 | )
Tax credits and receivables |  |  | 23 |  |  |  | (434 | )
Prepaid expenses and other assets |  |  | 190 |  |  |  | 212 |
Deferred cost of net revenue |  |  | (600 | ) |  |  | — |
Accounts payable |  |  | (193 | ) |  |  | 925 |
Deferred revenue and other liabilities |  |  | (1,192 | ) |  |  | 56 |
Net cash used in operating activities |  |  | (13,419 | ) |  |  | (7,057 | )
Cash flows from investing activities: |  |  |  |  |  |  |  |
Purchases of property and equipment |  |  | (577 | ) |  |  | (57 | )
Purchases of intangible assets |  |  | (21 | ) |  |  | (95 | )
Proceeds from maturities of marketable securities |  |  | 11,534 |  |  |  | — |
Purchases of marketable securities |  |  | (497 | ) |  |  | — |
Net cash provided by (used in) investing activities |  |  | 10,439 |  |  |  | (152 | )
Cash flows from financing activities: |  |  |  |  |  |  |  |
Taxes paid to net share settle equity awards |  |  | (61 | ) |  |  | — |
Repayment of loans |  |  | — |  |  |  | (184 | )
Proceeds from exercise of stock options |  |  | — |  |  |  | 31 |
Net proceeds from loan facility |  |  | — |  |  |  | 1,262 |
Net proceeds from convertible debenture |  |  | — |  |  |  | 5,545 |
Net cash provided by (used in) financing activities |  |  | (61 | ) |  |  | 6,654 |
Net decrease in cash and cash equivalents |  |  | (3,041 | ) |  |  | (555 | )
Cash and cash equivalents at beginning of period |  |  | 5,893 |  |  |  | 1,712 |
Cash and cash equivalents at end of period |  | $ | 2,852 |  |  | $ | 1,157 |
Supplemental disclosure: |  |  |  |  |  |  |  |
Recognition of right-of-use assets and lease liabilities |  | $ | 1,003 |  |  | $ | — |
Unrealized loss on available-for-sale securities |  | $ | 36 |  |  | $ | — |
Settlement of loan facility against tax receivables |  | $ | — |  |  | $ | 1,093 |
Fair value of new warrants issued recognized as debt discount |  | $ | — |  |  | $ | 2,604 |

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

PERASO INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1. The Company and Summary of Significant Accounting Policies

Peraso Inc., formerly known as MoSys, Inc. (the Company), was incorporated in California in 1991 and reincorporated in 2000 in Delaware. The Company is a fabless semiconductor company specializing in the development of millimeter wave (mmWave), which is generally described as the frequency band from 24 Gigahertz (GHz) to 300GHz, wireless technology. The Company derives revenue from selling its 60GHz and 5G semiconductor devices and modules and performance of non-recurring engineering services. The Company also manufactures and sells high-performance memory semiconductor devices for a wide range of markets and receives royalties from licensees of its memory technology.

On September 14, 2021, the Company and its subsidiaries, 2864552 Ontario Inc. (Callco) and 2864555 Ontario Inc. (Canco), entered into an Arrangement Agreement (the Arrangement Agreement) with Peraso Technologies Inc. (Peraso Tech), a corporation existing under the laws of the province of Ontario, to acquire all of the issued and outstanding common shares of Peraso Tech (the Peraso Shares), including those Peraso Shares to be issued in connection with the conversion or exchange of secured convertible debentures and common share purchase warrants of Peraso Tech, as applicable, by way of a statutory plan of arrangement (the Arrangement) under the Business Corporations Act (Ontario). On December 17, 2021, following the satisfaction of the closing conditions set forth in the Arrangement Agreement, the Arrangement was completed and, the Company changed its name to “Peraso Inc.” and began trading on the Nasdaq Stock Market (the Nasdaq) under the symbol “PRSO.”

For accounting purposes, Peraso Tech, the legal subsidiary, has been treated as the accounting acquirer and the Company, the legal parent, has been treated as the accounting acquiree. The transaction was accounted for as a reverse acquisition in accordance with Financial Accounting Standards Board Accounting Standards Codification (ASC) No. 805, Business Combinations (ASC 805). Accordingly, these condensed consolidated financial statements are a continuation of Peraso Tech’s consolidated financial statements prior to December 17, 2021 and exclude the statements of operations and comprehensive loss, statement of stockholders’ equity and statements of cash flows of the Company prior to December 17, 2021. See Note 2 for additional disclosure.

The accompanying condensed consolidated financial statements of the Company have been prepared without audit.

The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited consolidated financial statements at that date. Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (GAAP) have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s consolidated financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. The operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022 or for any other future period.

Liquidity

The Company incurred net losses of approximately $17.8 million for the nine months ended September 30, 2022 and $10.9 million for the year ended December 31, 2021 and had an accumulated deficit of approximately $135.0 million as of September 30, 2022. These and prior year losses have resulted in significant negative cash flows and have required the Company to raise substantial amounts of additional capital. To date, the Company has primarily financed its operations through multiple offerings of common stock and issuance of convertible notes and loans to investors and affiliates.

7

The Company expects to continue to incur operating losses for the foreseeable future as it secures additional customers and continues to invest in the commercialization of its products. The Company will need to increase revenues substantially beyond levels that it has attained in the past in order to generate sustainable operating profit and sufficient cash flows to continue doing business without raising additional capital from time to time. As a result of the Company’s expected operating losses and cash burn for the foreseeable future, as well as recurring losses from operations, if the Company is unable to raise sufficient capital through additional debt or equity arrangements, there will be uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company’s ability to continue as a going concern within one year from the date of issuance of these condensed consolidated financial statements. These condensed consolidated financial statements do not include any adjustments that might result from this uncertainty. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions acceptable to the Company. The Company’s primary focus is producing and selling its products. If the Company is unsuccessful in these efforts, it will need to implement additional cost reduction strategies, which could further affect its near- and long-term business plan. These efforts may include, but are not limited to, reducing headcount and curtailing business activities.

Basis of Presentation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The Company’s fiscal year ends on December 31 of each calendar year. Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows. The Company previously classified intangible asset amortization expense related to the developed technology and customer relationships intangibles within research and development expenses (R&D) in its condensed consolidated statements of operations and comprehensive loss. Amortization expense on the developed technology intangible asset is now classified within cost of net revenue, and amortization expense on customer relationships is now classified in selling, general and administrative expenses (SG&A). Prior period amounts have been conformed to the current period presentation. See Note 5 for additional disclosure.

Risks and Uncertainties

The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets.

COVID-19

The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in-place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company’s operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company’s control, and cannot be predicted.

Use of Estimates

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses recognized during the reported period. Material estimates may include assumptions made in determining reserves for uncollectible receivables, inventory write-downs, impairment of long-term assets, purchase price allocations, valuation allowance on deferred tax assets, accruals for potential liabilities and assumptions made in valuing equity instruments. Actual results could differ from those estimates.

Cash Equivalents and Investments

The Company has invested its excess cash in money market accounts, certificates of deposit, corporate debt, government-sponsored enterprise bonds and municipal bonds and considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Investments with original maturities greater than three months and remaining maturities less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. Management generally determines the appropriate classification of securities at the time of purchase. All securities are classified as available-for-sale. The Company’s available-for-sale short-term and long-term investments are carried at fair value, with the unrealized holding gains and losses reported in accumulated other comprehensive income (loss). Realized gains and losses and declines in the value judged to be other-than-temporary are included in the other income, net line item in the condensed consolidated statements of operations. The cost of securities sold is based on the specific identification method.

8

Fair Value Measurements

The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels:

Level 1—Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date.

Level 2—Pricing is provided by third party sources of market information obtained through the Company’s investment advisors, rather than models. The Company does not adjust for, or apply, any additional assumptions or estimates to the pricing information it receives from advisors. The Company’s Level 2 securities include cash equivalents and available-for-sale securities, which consisted primarily of certificates of deposit, corporate debt, and government agency and municipal debt securities from issuers with high-quality credit ratings. The Company’s investment advisors obtain pricing data from independent sources, such as Standard & Poor’s, Bloomberg and Interactive Data Corporation, and rely on comparable pricing of other securities because the Level 2 securities are not actively traded and have fewer observable transactions. The Company considers this the most reliable information available for the valuation of the securities.

Level 3—Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment are used to measure fair value. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 investments and other financial instruments involves the most management judgment and subjectivity.

The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, accounts receivable, accounts payable, notes payable and other payables, approximate their fair values because of the short maturity of these instruments. The carrying values of lease obligations and long-term financing obligations approximate their fair values because interest rates on these obligations are based on prevailing market interest rates.

Allowance for Doubtful Accounts

The Company establishes an allowance for doubtful accounts to ensure that its trade receivables balances are not overstated due to uncollectibility. The Company performs ongoing customer credit evaluations within the context of the industry in which it operates and generally does not require collateral from its customers. A specific allowance of up to 100% of the invoice value is provided for any problematic customer balances. Delinquent account balances are written off after management has determined that the likelihood of collection is remote. The Company grants credit only to customers deemed creditworthy in the judgment of management. The allowance for doubtful accounts receivable was approximately $683,000 as of September 30, 2022 and approximately $61,000 as of December 31, 2021.

Inventories

The Company values its inventories at the lower of cost, which approximates actual cost on a first-in, first-out basis, or net realizable value. Costs of inventories primarily consisted of material and third party assembly costs. The Company records inventory reserves for estimated obsolescence or unmarketable inventories based upon assumptions about future demand and market conditions. Once a reserve is established, it is maintained until the product to which it relates is sold or otherwise disposed of. If actual market conditions are less favorable than those expected by management, additional adjustment to inventory valuation may be required. Charges for obsolete and slow-moving inventories are recorded based upon an analysis of specific identification of obsolete inventory items and quantification of slow moving inventory items. The Company recorded write-downs of inventory of approximately $420,000 and $56,000 during the nine months ended September 30, 2022 and 2021, respectively.

Tax Credits and Receivables

The Company is registered for the Canadian federal and provincial goods and services taxes. As such, the Company is obligated to collect from third parties and is entitled to claim sales taxes paid on its expenses and capital expenditures incurred in Canada.

The Company participated in the Canadian government’s Scientific Research and Experimental Development (SRED) Program, which uses tax incentives to encourage Canadian businesses to conduct research and development (R&D) in Canada. As a part of the program, the Company may be entitled to a receivable in the form of tax credits or incentives. The Company records refundable tax credits as a reduction of expense and receivable when the Company can reasonably estimate the amounts and it is more likely than not, the credit will be received.

A government refund or subsidy that is compensation for expenses or losses already incurred, or for which there are no future related costs, is recognized in the statement of operations in the period in which it becomes receivable.

9

As of December 17, 2021, Peraso Tech ceased to be a Canadian Controlled Private Corporation, as defined by the government of Canada, and the Company is no longer eligible for the expenditure refund program. However, it is eligible for a tax credit of 15% on qualified SRED expenditures. Unused SRED tax credits can be carried back three years or forward for 20 years.

Intangible and Long-lived Assets

Intangible assets are recorded at cost and amortized on a straight-line method over their estimated useful lives of three to ten years. Amortization of developed technology and other intangibles directly related to the Company’s products is included in cost of net revenue, while amortization of customer relationships and other intangibles not associated with the Company’s products is included in SG&A in the condensed consolidated statements of operations.

The Company regularly reviews the carrying value and estimated lives of its long-lived assets and finite-lived intangible assets to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management’s estimate of the asset’s ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company’s business objective. Should an impairment exist, the impairment loss would be measured based on the excess of the carrying amount of the long-lived asset group over the asset’s fair value.

Purchased Intangible Assets

Intangible assets acquired in business combinations are accounted for based on the fair value of assets purchased and are amortized over the period in which economic benefit is estimated to be received. Intangible assets subject to amortization, including those acquired in business combinations were as follows (amounts in thousands):

|  | September 30, 2022 |
|  | Gross |  |  |  |  |  |  | Net |
|  | Carrying |  |  | Accumulated |  |  | Carrying |
|  | Amount |  |  | Amortization |  |  | Amount |
Developed technology |  | $ | 5,726 |  |  | $ | 1,133 |  |  | $ | 4,593 |
Customer relationships |  |  | 2,556 |  |  |  | 506 |  |  |  | 2,050 |
Other |  |  | 186 |  |  |  | 26 |  |  |  | 160 |
Total |  | $ | 8,468 |  |  | $ | 1,665 |  |  | $ | 6,803 |

|  | December 31, 2021 |
|  | Gross |  |  |  |  |  |  | Net |
|  | Carrying |  |  | Accumulated |  |  | Carrying |
|  | Amount |  |  | Amortization |  |  | Amount |
Developed technology |  | $ | 5,726 |  |  | $ | 60 |  |  | $ | 5,666 |
Customer relationships |  |  | 2,556 |  |  |  | 27 |  |  |  | 2,529 |
Other |  |  | 165 |  |  |  | 5 |  |  |  | 160 |
Total |  | $ | 8,447 |  |  | $ | 92 |  |  | $ | 8,355 |

Developed technology primarily consisted of MoSys’ products that have reached technological feasibility and primarily relate to its memory semiconductor products and technology. The value of the developed technology was determined by discounting estimated net future cash flows of these products. The Company is amortizing the developed technology on a straight-line basis over four years. Amortization related to developed technology of $0.4 million and $1.1 million for the three and nine months ended September 30, 2022, respectively, has been included in cost of net revenue in the condensed consolidated statements of operations and comprehensive loss.

Customer relationships relate to the Company's ability to sell existing and future versions of products to MoSys’ customers existing at the time of the arrangement. The fair value of the customer relationships was determined by discounting estimated net future cash flows from the customer relationships. The Company is amortizing customer relationships on a straight-line basis over an estimated life of 4 years. Amortization related to customer relationships of $0.2 million and $0.5 million for the three and nine months ended September 30, 2022, respectively, has been included in selling, general and administrative expense in the condensed consolidated statements of operations and comprehensive loss.

Amortization expense was $0.5 million and $1.6 million for the three and nine months ended September 30, 2022, respectively. There was no material amortization expense for the three and nine months ended September 30, 2021.

10

As of September 30, 2022, estimated future amortization expense related to intangible assets was as follows (in thousands):

Year ending December 31, |  |  |  |
2022 |  | $ | 526 |
2023 |  |  | 2,099 |
2024 |  |  | 2,099 |
2025 |  |  | 2,011 |
2026 |  |  | 28 |
2027 |  |  | 10 |
Thereafter |  |  | 30 |
|  | $ | 6,803 |

Goodwill

The Company determines the amount of a potential goodwill impairment by comparing the fair value of the reporting unit with its carrying amount. To the extent the carrying value of a reporting unit exceeds its fair value, a goodwill impairment charge is recognized.

The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test. As the Company uses the market approach to determine the step one fair value of the reporting unit, the price of its common stock is an important component of the fair value calculation. If the Company’s stock price experiences significant price and volume fluctuations, this will impact the fair value of the reporting unit, which can lead to potential impairment in future periods. The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The Company first assesses qualitative factors to determine whether it is more-likely-than-not that the fair value of the reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform an impairment test. If the qualitative assessment warrants further analysis, the Company compares the fair value of the reporting unit to its carrying value. The fair value of the reporting unit is determined using the market approach. If the fair value of the reporting unit exceeds the carrying value of net assets of the reporting unit, goodwill is not impaired. If the carrying value of the reporting unit’s goodwill exceeds its fair value, then the Company must record an impairment charge equal to the difference.

To date, as of September 30, 2022, the Company has not identified any goodwill impairment. However, current macroeconomic conditions, which have been impacted by the COVID-19 pandemic and inflation, could negatively impact our business and stock price and trigger the Company to test for impairment. The Company will continue to evaluate for impairment indicators, as necessary, on a quarterly basis.

.

Leases

ASC No. 842, Leases (ASC 842) requires an entity to recognize a right-of-use asset and a lease liability for all leases with terms longer than 12 months. The Company adopted ASC 842 utilizing the modified retrospective transition method. The Company elected the practical expedient afforded in ASC 842 in which the Company did not reassess whether any contracts that existed prior to adoption have or contain leases or the classification of its existing leases.

Revenue Recognition

The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers and its amendments (ASC 606). As described below, the analysis of contracts under ASC 606 supports the recognition of revenue at a point in time, resulting in revenue recognition timing that is materially consistent with the Company’s historical practice of recognizing product revenue when title and risk of loss pass to the customer.

The Company generates revenue primarily from sales of integrated circuits and module products, performance of engineering services and licensing of its intellectual property. Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.

11

P roduct revenue

Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied. The majority of the Company's contracts have a single performance obligation to transfer products. Accordingly, the Company recognizes revenue when title and risk of loss have been transferred to the customer, generally at the time of shipment of products. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products and is generally based upon a negotiated, formula, list or fixed price. The Company sells its products both directly to customers and through distributors generally under agreements with payment terms typically 60 days or less.

The Company may record an estimated allowance, at the time of shipment, for future returns and other charges against revenue consistent with the terms of sale.

Royalty and other

The Company’s licensing contracts typically provide for royalties based on the licensee’s use of the Company’s memory technology in its currently shipping commercial products. The Company estimates its royalty revenue in the calendar quarter in which the licensee uses the licensed technology. Payments are received in the subsequent quarter. The Company also generates revenue from licensing its technology. The Company recognizes license fees as revenue at the point of time when the control of the license has been transferred and the Company has no continuing performance obligations to the customer.

Engineering services revenue

Engineering and development contracts with customers generally contain a single performance obligation that is delivered over time. Revenue is recognized using an output method that is consistent with the satisfaction of the performance obligation as a measure of progress.

Deferred Cost of Net Revenue

During the three months ended September 30, 2022, the Company had $1.1 million of product shipments for which the revenue recognition criteria under ASC 606 had not been met. Accordingly, the Company has deferred the cost of net revenue associated with these shipments, and the amount deferred has been presented as deferred cost of net revenue in the condensed consolidated balance sheets.

Contract liabilities – deferred revenue

The Company’s contract liabilities consist of advance customer payments and deferred revenue. The Company classifies advance customer payments and deferred revenue as current or non-current based on the timing of when the Company expects to recognize revenue. As of September 30, 2022 and December 31, 2021, contract liabilities were in a current position and included in deferred revenue.

During the nine months ended September 30, 2022, the Company recognized approximately $156,000 of revenue that had been included in deferred revenue as of December 31, 2021.

See Note 7 for disaggregation of revenue by geography.

The Company does not have significant financing components, as payments from customers are typically due within 60 days of invoicing, and the Company has elected the practical expedient to not value financing components that are less than one year. Shipping and handling costs are generally incurred by the customer, and, therefore, are not recorded as revenue.

Cost of Net Revenue

Cost of net revenue consists primarily of direct and indirect costs of product sales, including amortization of intangible assets and depreciation of production-related fixed assets.

Government Subsidies

A grant or subsidy that is compensation for expenses or losses already incurred, or for which there are no future related costs, is recognized in the statement of operations in the period in which it becomes receivable.

Starting in 2020, certain Canadian businesses, which experienced a drop in revenue during the COVID-19 pandemic, became eligible for rent and wage subsidies from the Canadian government. The Company’s subsidiary, Peraso Tech, began receiving subsidies on a monthly basis beginning in the fourth quarter of 2020 and ending in the fourth quarter of 2021.

12

During the nine months ended September 30, 2021, the Company recognized payroll subsidies of $1,102,616 as a reduction in the associated wage costs and rent subsidies of $195,995 as a reduction of operating expenses in the condensed consolidated statement of operations.

Stock-Based Compensation

The Company periodically issues stock options and restricted stock awards to employees and non-employees. The Company accounts for such grants based on ASC No. 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on a straight-line basis over the vesting period. The fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing (Black Scholes) model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes model. The assumptions used in the Black-Scholes model could materially affect compensation expense recorded in future periods.

Foreign Currency Transactions

The functional currency of the Company is the U.S dollar. All foreign currency transactions are initially measured and recorded in an entity’s functional currency using the exchange rate on the date of the transaction. All monetary assets and liabilities are remeasured at the end of each reporting period using the exchange rate at that date. All non-monetary assets and related expense, depreciation or amortization are not subsequently remeasured and are measured using the historical exchange rate. An average exchange rate may be used to recognize income and expense items earned or incurred evenly over a period. Foreign exchange gains and losses resulting from the settlement of such transactions are recognized in the statement of operations, except for the gains and losses arising from the conversion of the carrying amount of the foreign currency denominated convertible preferred shares into the functional currency that are presented as adjustment to the net loss to arrive at net loss attributable to common stockholders.

Per-Share Amounts

Basic net loss per share is computed by dividing net loss for the period by the weighted-average number of exchangeable shares and shares of common stock outstanding during the period. Diluted net loss per share gives effect to all potentially dilutive exchangeable and common shares outstanding during the period. Potentially dilutive common shares consist of incremental exchangeable shares and shares of common stock issuable upon the achievement of escrow terms, exercise of stock options, vesting of stock awards and exercise of warrants.

The following table sets forth securities outstanding that were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands):

|  | September 30, |
|  | 2022 |  |  | 2021 |
Escrow shares - exchangeable shares |  |  | 1,313 |  |  |  | — |
Escrow shares - common stock |  |  | 502 |  |  |  | — |
Options to purchase common stock |  |  | 1,514 |  |  |  | 1,034 |
Unvested restricted common stock units |  |  | 1,229 |  |  |  | — |
Convertible debt |  |  | — |  |  |  | 5,500 |
Common stock warrants |  |  | 134 |  |  |  | 508 |
Total |  |  | 4,692 |  |  |  | 7,042 |

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-13, Financial Instruments—Credit Losses. This ASU added a new impairment model (known as the current expected credit loss (CECL) model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes an allowance for its estimate of expected credit losses and applies to most debt instruments, trade receivables, lease receivables, financial guarantee contracts, and other loan commitments. The CECL model does not have a minimum threshold for recognition of impairment losses and entities will need to measure expected credit losses on assets that have a low risk of loss. This update is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years for smaller reporting companies. The Company does not expect that the adoption of ASU No. 2016-13 will have a significant impact on the Company's consolidated financial statements.

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718), and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (ASU 2021-04). ASU 2021-04 provides guidance as to how an issuer should account for a modification of the terms or

13

conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. The Company adopted ASU 2021-04 effective January 1, 2022. The adoption of ASU 2021-04 did not have any impact on the Company’s consolidated financial statement presentation or disclosures.

Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Note 2: Business Combination

Arrangement

As discussed in Note 1, on September 14, 2021, the Company and its newly formed subsidiaries, Callco and Canco, entered into the Arrangement Agreement with Peraso Tech. Prior to the Arrangement, as a fabless semiconductor company, the Company’s primary focus was the manufacture and sale of high-performance memory semiconductor devices for a wide range of markets. Peraso Tech was also a fabless semiconductor company specializing in the development of mmWave technology, including 60GHz and 5G products, and deriving revenue from selling semiconductor devices, proprietary modules based on its semiconductor devices and performance of non-recurring engineering services. The primary reason for the business combination was to produce a larger fabless semiconductor company with greater size and scale with access to the public capital markets for the benefit of the stockholders of both companies.

On December 17, 2021, following the satisfaction of the closing conditions set forth in the Arrangement Agreement, including approvals from the stockholders of the Company and Peraso Tech, the Arrangement was completed.

Securities Conversion

Pursuant to the completion of the Arrangement, each Peraso Share that was issued and outstanding immediately prior to December 17, 2021 was converted into the right to receive 0.045239122387267 (the Exchange Ratio) newly issued shares of common stock of the Company or shares of Canco, which are exchangeable for shares of the Company’s common stock (Exchangeable Shares), at the election of each former Peraso Tech stockholder. In addition, all of Peraso Tech’s outstanding stock options and other securities exercisable or exchangeable for, or convertible into, and any other rights to acquire Peraso Shares were exchanged for securities exercisable or exchangeable for, or convertible into, or other rights to acquire the Company’s common stock. Immediately following the completion of the Arrangement, the former security holders of Peraso Tech owned approximately 61%, on a fully-diluted basis, of the Company’s common stock, and the former shareholders of Peraso Tech, as a group, obtained control of the Company. While the Company was the legal acquirer of Peraso Tech, Peraso Tech was deemed to be the acquirer for accounting purposes.

In addition, pursuant to the terms of the Arrangement Agreement, (i) certain warrants to purchase Peraso Shares outstanding immediately prior to the closing of the Arrangement were exercised in consideration for the issuance of Peraso Shares; (ii) each convertible debenture of Peraso Tech outstanding immediately prior to the closing of the Arrangement and all principal and accrued but unpaid interest thereon was converted into Peraso Shares at a conversion price equal to the conversion price set out in each such debenture; and (iii) each outstanding option to purchase Peraso Shares (each, a Peraso Option) was exchanged for a replacement option to purchase such number of shares of common stock that was equal to the product of (a) the number of Peraso Shares subject to the Peraso Options immediately before the closing of the Arrangement and (b) the Exchange Ratio, rounded down to the nearest whole number of shares of common stock.

Upon the closing of the Arrangement, an aggregate of 9,295,097 Exchangeable Shares and 3,558,151 shares of common stock were issued to the holders of Peraso Shares. Of such shares, pursuant to the terms of the Agreement, the Company held in escrow an aggregate of 1,312,878 Exchangeable Shares and 502,567 shares of common stock (collectively, the Escrow Shares). The Escrow Shares are escrowed pursuant to the terms of an escrow agreement on a pro rata basis from the aggregate consideration received by the holders of Peraso Shares, subject to the offset by the Company for any losses in accordance with the Agreement. Such Escrow Shares shall be released, subject to any offset claim, upon the satisfaction of the earlier of: (a) any date following the first anniversary of December 17, 2021 and prior to December 17, 2024 where the volume weighted average price of the common stock for any 20 trading days within a period of 30 consecutive trading days is at least $8.57 per share, subject to adjustment for stock splits or other similar transactions; (b) the date of any sale of all or substantially all of the assets or shares of the Company; or (c) the date of any bankruptcy,

14

insolvency, restructuring, receivership, administration, wind-up, liquidation, dissolution, or similar event involving the Company. All and any voting rights and other stockholder rights, other than with respect to dividends and distributions, with respect to the Escrow Shares are suspended until the Escrow Shares are released from escrow.

The Exchangeable Share structure is commonly used for cross-border transactions of this nature so as to provide non-tax-exempt Canadian shareholders with the same economic rights and benefits as holders of the Company’s shares into which the Exchangeable Shares are exchangeable, while allowing those Canadian shareholders to benefit from the tax-rollover available on the issuance of the Exchangeable Shares. In general terms, by choosing to acquire Exchangeable Shares from Canco, such a former Peraso Tech shareholder was able to rely on a rollover rule in the Income Tax Act (Canada) in order to defer any capital gain that he/she/it would have otherwise realized.

Callco was incorporated to exercise the call rights, while Canco was incorporated to acquire the shares of Peraso Tech from Canadian shareholders that wished to receive Exchangeable Shares as consideration, so it was a tax deferred transaction for such Canadian shareholders. The use of a separate entity, Callco, helps maximize cross border paid-up capital, which represents the amount that can generally be distributed free of Canadian withholding tax. The call rights also allow Callco to “purchase” the Exchangeable Shares rather than having them redeemed by Canco on a redemption or retraction or in connection with a liquidity event, thus avoiding the adverse deemed dividend tax consequences to shareholders that may arise from a redemption or retraction of Exchangeable Shares.

Holders of Exchangeable Shares have the right at any time (the Retraction Right) to retract or redeem any or all of the Exchangeable Shares owned by them for an amount per share equal to the market price of a share of the Company’s common stock plus the full amount of all declared and unpaid dividends on such Exchangeable Share (the Exchangeable Share Purchase Price). The Exchangeable Share Purchase Price is payable only by the Company delivering or causing to be delivered to the relevant holder one share of the Company’s common stock for each Exchangeable Share purchased plus a cash amount equal to the amount of any accrued and unpaid dividends on such Exchangeable Share. The Company and Callco each have an overriding right, in the event that a holder of Exchangeable Shares exercises its Retraction Right, to redeem from such holder all, but not less than all, of the Exchangeable Shares tendered for redemption.

The Exchangeable Shares are subject to redemption by the Company, Callco and Canco at the Exchangeable Share Purchase Price, on the “Redemption Date,” which date shall be no earlier than the seventh anniversary of the date on which Exchangeable Shares are first issued, unless: (a) less than 10% of the aggregate number of Exchangeable Shares issued remain outstanding; (b) there is a change in control of the Company (defined generally as (i) any merger, amalgamation, arrangement, takeover bid or tender offer, material sale of shares or rights or interests that results in the holders of outstanding voting securities of the Company directly or indirectly owning, or exercising control or direction over, voting securities representing less than 50% of the total voting power of all of the voting securities of the surviving entity; or (ii) any sale or disposition of all or substantially of the Company’s assets), and (c) upon the occurrence of certain other events. The Exchangeable Share Purchase Price is payable only by the Company delivering or causing to be delivered to the relevant holder one share of the Company’s common stock for each Exchangeable Share purchased plus a cash amount equal to the amount of any accrued and unpaid dividends on such Exchangeable Share.

In the event of the liquidation, dissolution or winding-up of Canco, holders of Exchangeable Shares have the right to receive in respect of each Exchangeable Share held by such holder, an amount per share equal to the Exchangeable Share Purchase Price, which shall be satisfied in full by Canco by delivering to such holder one Company Share, plus an amount equal to the Dividend Amount. The Company and Callco each have an overriding right to purchase from all holders all but not less than all of the Exchangeable Shares upon the occurrence of such events.

In addition, the Company and Callco have the right to purchase all outstanding Exchangeable Shares at the Exchangeable Share Purchase Price if there is a change of law that permits holders of Exchangeable Shares to exchange their Exchangeable Shares for shares of common stock on a basis that will not require holders to recognize any gain or loss or any actual or deemed dividend for Canadian tax purposes.

The holders of Exchangeable Shares have an “automatic exchange right” in the event of any insolvency, liquidation, dissolution or winding-up or in general, related proceedings, of the Company for an amount per share equal to the Exchangeable Share Purchase Price.

It is expected that Callco will exercise its call rights, as that is more beneficial to the holders of the Exchangeable Shares. Once Callco acquires the Exchangeable Shares from a holder, it (Callco and the Company) is obligated to deliver the Company shares to the holder. Callco discharges this obligation by arranging for the Company to issue and deliver those shares to the holders on behalf of Callco. As consideration for satisfying the delivery obligation, Callco would issue its own shares to the Company.

15

There are no cash redemption features, as all redemption and exchange scenarios are payable in a share of the Company’s common stock. Neither Canco, Callco, or the Company assume any tax liabilities of a former Peraso Tech shareholder who acquired Exchangeable Shares under the plan of arrangement. The purchase price computed upon the exercise of rights pertaining to retraction, redemption, or liquidation, or otherwise giving rise to a purchase or cancellation of an Exchangeable Share, will, in all cases, consist of a 1:1 exchange involving the Company’s common stock, regardless of the market price of a share of the Company’s common stock.

In connection with the Arrangement, on December 15, 2021, the Company filed the Certificate of Designation of Series A Special Voting Preferred Stock (the Certificate) with the Secretary of State of the State of Delaware to designate Series A Special Voting Preferred Stock (the Special Voting Share) in accordance with the terms of the Arrangement Agreement in order to enable the holders of Exchangeable Shares to exercise their voting rights. The Special Voting Share was issued to a third-party administrative agent (the Agent) solely to facilitate the exercise of rights by holders of Exchangeable Shares. The rights of the Agent, as holder of the Special Voting Share, are limited to effecting the rights of the holders of the Exchangeable Shares; the Special Voting Share does not confer any independent rights to the Agent. Under the Certificate, when all of the Exchangeable shares have been converted into shares of the Company’s common stock, the Special Voting Share shall be automatically cancelled and shall not be reissued. Each Exchangeable Share is exchangeable for one share of common stock of the Company and while outstanding, the Special Voting Share enables holders of Exchangeable Shares to cast votes on matters for which holders of the common stock are entitled to vote, and by virtue of the share terms relating to the Exchangeable Shares, enable the Exchangeable Shares to receive dividends that are economically equivalent to any dividends declared with respect to the shares of common stock. As the Special Voting Share does not participate in dividends (only the Exchangeable Shares participate in dividends) and is not entitled to participate in the residual interest of the Company, it is not classified as an equity instrument in the Company’s financial statements.

The Exchangeable Shares, which can be converted into common stock at the option of the holder and have the same voting and dividend rights as common stock, are similar in substance to shares of common stock. Further, Canco and Callco are non-substantive entities, which are looked through with the Exchangeable Shares being, in substance, common stock of the Company. Therefore, the Exchangeable Shares have been included in the determination of outstanding common stock. The Special Voting Share was issued to a third-party administrative agent (the Agent) solely to facilitate the exercise of rights by holders of Exchangeable Shares, The rights of the Agent, as holder of the Special Voting Share, are limited to effecting the rights of the holders of the Exchangeable Shares; the Special Voting Share does not confer any independent rights to the Agent. Under the Certificate, when all of the Exchangeable shares have been converted into shares of the Company’s common stock, the Special Voting Share shall be automatically cancelled and shall not be reissued.

Reverse Acquisition Determination

Pursuant to ASC 805, the transaction was accounted for as a reverse acquisition because: (i) the stockholders of Peraso Tech owned the majority of the outstanding common stock of the Company after the share exchange; (ii) Peraso Tech appointed a majority of the Company’s board of directors; and (iii) Peraso Tech determined the officers of the Company.

16

Measuring the Consideration Transferred

In the reverse acquisition, the accounting acquirer did not issue any consideration to the accounting acquiree, rather the accounting acquiree issued its equity shares to the owners of the accounting acquirer in exchange for the accounting acquirer’s shares. The acquisition date fair value of the consideration transferred by the accounting acquirer for its interest in the accounting acquiree was calculated by Peraso Tech, as the fair value of the consideration effectively transferred. In accordance with ASC 805, the consideration effectively transferred between the Company (a public company as the accounting acquiree) and Peraso Tech (a private company as the accounting acquirer), was calculated as the fair value of the Company’s equity including the fair value of its common shares outstanding and its warrants, plus the portion of the share-based award fair value allocated to the pre-combination service of the accounting acquiree’s awards. The fair value of the total consideration effectively transferred is summarized in the following table (in thousands, except per-share amount):

Company share price (i) |  | $ | 4.21 |
Company common shares outstanding (ii) |  |  | 8,716 |
Fair value of the Company's common shares outstanding |  |  | 36,694 |
Fair value of the Company's warrants (iii) |  |  | 301 |
Total fair value of the Company's share-based awards (iii) |  |  | 782 |
Percent related to pre-combination service |  |  | 80.76 | %
Fair value of the Company's pre-combination service share-based awards (iii) |  |  | 632 |
Consideration effectively transferred |  | $ | 37,627 |
(i) Represents the Company's share price as of December 16, 2021 |
(ii) Represents the Company's outstanding shares as of December 16, 2021 |
(iii) Represents the fair value of the Company's warrants outstanding and calculated as of December 16, 2021 |

The following table summarizes the final allocation of the purchase price to the net assets acquired based on the respective fair value of the acquired assets and assumed liabilities of the accounting acquiree, which is the Company.

|  | December 31, |
|  | 2021 |
Assets: |  | (in thousands) |
Cash, cash equivalents and investments |  | $ | 19,064 |
Other current assets |  |  | 2,558 |
Other assets |  |  | 833 |
Intangibles |  |  |  |
Developed technology |  |  | 5,726 |
Customer relationships |  |  | 2,556 |
|  |  | 8,282 |
Goodwill |  |  | 9,946 |
Liabilities: |  |  |  |
Current liabilities |  |  | 3,056 |
|  | $ | 37,627 |

17

Unaudited pro forma results of operations for the three and nine months ended September 30, 2021 are included below as if the business combination occurred on January 1, 2021. This summary of the unaudited pro forma results of operations is not necessarily indicative of what the Company’s results of operations would have been had Peraso Tech been acquired at the beginning of 2021, nor does it purport to represent results of operations for any future periods.

|  | Three Months Ended |  |  | Nine Months Ended |
(in thousands) |  | September 30, 2021 |  |  | September 30, 2021 |
Revenue |  | $ | 3,354 |  |  | $ | 7,659 |
Net loss |  | $ | (5,535 | ) |  | $ | (17,695 | )

Note 3: Fair Value of Financial Instruments

The estimated fair values of financial instruments outstanding were (in thousands):

|  | September 30, 2022 |
|  |  |  |  |  | Unrealized |  |  | Unrealized |  |  | Fair |
|  | Cost |  |  | Gains |  |  | Loss |  |  | Value |
Cash and cash equivalents |  | $ | 2,852 |  |  | $ | — |  |  | $ | — |  |  | $ | 2,852 |
Short-term investments |  |  | 1,107 |  |  |  | — |  |  |  | (36 | ) |  |  | 1,071 |
|  | $ | 3,959 |  |  | $ | — |  |  | $ | (36 | ) |  | $ | 3,923 |

|  | December 31, 2021 |
|  |  |  |  |  | Unrealized |  |  | Unrealized |  |  | Fair |
|  | Cost |  |  | Gains |  |  | Losses |  |  | Value |
Cash and cash equivalents |  | $ | 5,893 |  |  | $ | — |  |  | $ | — |  |  | $ | 5,893 |
Short-term investments |  |  | 9,276 |  |  |  | — |  |  |  | (9 | ) |  |  | 9,267 |
Long-term investments |  |  | 2,935 |  |  |  | — |  |  |  | (7 | ) |  |  | 2,928 |
|  | $ | 18,104 |  |  | $ | — |  |  | $ | (16 | ) |  | $ | 18,088 |

The following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands):

|  | September 30, 2022 |
|  | Fair Value |  |  | Level 1 |  |  | Level 2 |  |  | Level 3 |
Money market funds |  | $ | 72 |  |  | $ | 72 |  |  | $ | — |  |  | $ | — |
Corporate notes and commercial paper |  | $ | 1,071 |  |  | $ | — |  |  | $ | 1,071 |  |  | $ | — |
|  | $ | 1,143 |  |  | $ | 72 |  |  | $ | 1,071 |  |  | $ | — |

|  | December 31, 2021 |
|  | Fair Value |  |  | Level 1 |  |  | Level 2 |  |  | Level 3 |
Money market funds |  | $ | 1,159 |  |  | $ | 1,159 |  |  | $ | — |  |  | $ | — |
Corporate notes and commercial paper |  | $ | 12,195 |  |  | $ | — |  |  | $ | 12,195 |  |  | $ | — |

There were no transfers in or out of Level 1 and Level 2 securities during the nine months ended September 30, 2022 or December 31, 2021.

18

Note 4. Balance Sheet Detail

Inventories

|  | September 30, |  |  | December 31, |
|  | 2022 |  |  | 2021 |
|  | (in thousands) |
Raw materials |  | $ | 1,416 |  |  | $ | 879 |
Work-in-process |  |  | 2,728 |  |  |  | 2,170 |
Finished goods |  |  | 1,127 |  |  |  | 775 |
|  | $ | 5,271 |  |  | $ | 3,824 |

Note 5. Revision of Prior Period Financial Statements

Prior to April 1, 2022, the Company classified amortization expense related to the developed technology and customer relationships intangible assets within R&D in its condensed consolidated statements of operations and comprehensive loss. Amortization expense on the developed technology intangible asset is now classified within cost of net revenue, and amortization expense on customer relationships is now classified in SG&A. Prior period amounts have been conformed to the current period presentation. The reclassification had no impact on the Company's net loss or cash flows for the three months ended March 31, 2022 and nine months ended September 30, 2022.

The effects of the adjustments for the three months ended March 31, 2022 were as follows (in thousands):

|  | As Reported |  |  | Adjustment |  |  | As Revised |
Condensed Consolidated Statement of Operations: |  |  |  |  |  |  |  |  |  |  |  |
Cost of net revenue |  | $ | 1,590 |  |  | $ | 358 |  |  | $ | 1,948 |
Gross profit |  |  | 1,813 |  |  |  | (358 | ) |  |  | 1,455 |
Research and development |  |  | 6,003 |  |  |  | (517 | ) |  |  | 5,486 |
Selling, general and administrative |  |  | 2,546 |  |  |  | 159 |  |  |  | 2,705 |
Total operating expenses |  | $ | 8,549 |  |  | $ | (358 | ) |  | $ | 8,191 |

Note 6. Commitments and Contingencies

Leases

The Company has five facility leases that it accounts for under ASC 842, and these include the operating leases for its corporate facility in San Jose, California, and facilities in Toronto, Markham and Waterloo, Ontario, Canada. The Waterloo and Toronto leases expire in September 2022 and December 2023, respectively. The current San Jose lease with a sublessor expires in July 2022, and the Company entered into a new, direct lease with the facility landlord, dated April 13, 2022, for an 18-month term, which commenced July 15, 2022. In addition, on May 26, 2022, the Company entered into a new lease for a facility in Markham, Ontario with a 60-month term, which commenced June 21, 2022. The Markham landlord also provided a lease incentive of approximately $220,000 (the Incentive), which will be payable to the Company as follows: one-half of the Incentive payable subsequent to the completion of the improvements to the leased space and the second half-ratably on an annual basis commencing with the second year of the lease.

The right-to-use assets and corresponding liabilities for the facility leases were measured at the present value of the future minimum lease payments. The discount rate used to measure the lease assets and liabilities were 8%. Lease expense is recognized on a straight-line basis over the lease term.

19

On March 1, 2022, the Company entered into a 36-month finance lease agreement for the lease of equipment resulting in the recognition of a right-of-use asset and lease liability on the balance sheet of approximately $274,000.

The following table provides the details of right-of-use assets and lease liabilities as of September 30, 2022 (in thousands):

|  |  |  |  | Nine Months Ended |
|  |  |  |  | September 30, 2022 |
Right-of-use assets: |  |  |  |  |  |  |
Operating leases |  |  |  |  | $ | 957 |
Finance lease |  |  |  |  |  | 224 |
Total right-of-use assets |  |  |  |  | $ | 1,181 |
Lease liabilities: |  |  |  |  |  |  |
Operating leases |  |  |  |  | $ | 954 |
Finance lease |  |  |  |  |  | 233 |
Total lease liabilities |  |  |  |  | $ | 1,187 |

Future minimum payments under the leases at September 30, 2022 are listed in the table below (in thousands):

Year ending December 31, |  |  |  |  |  |  |
2022 |  |  |  |  | $ | 67 |
2023 |  |  |  |  |  | 742 |
2024 |  |  |  |  |  | 216 |
2025 |  |  |  |  |  | 132 |
2026 |  |  |  |  |  | 106 |
2027 |  |  |  |  |  | 67 |
Total future lease payments |  |  |  |  |  | 1,330 |
Less: imputed interest |  |  |  |  |  | (143 | )
Present value of lease liabilities |  |  |  |  | $ | 1,187 |

The following table provides the details of supplemental cash flow information (in thousands):

|  |  | Nine Months Ended |
|  |  | September 30, |
|  |  | 2022 |  |  | 2021 |
Cash paid for amounts included in the measurement of lease liabilities: |  |  |  |  |  |  |
Operating cash flows for leases |  | $ | 504 |  |  | $ | 273 |

Rent expense was approximately $0.2 million for each of the three-month periods ended September 30, 2022 and 2021. Rent expense was approximately $0.5 million for the nine months ended September 30, 2022 and $0.3 million for the nine months ended September 30, 2021. In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and certain other operating costs related to the leased facilities and equipment.

20

Indemnification

In the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into indemnification agreements with its officers and directors. No material amounts were reflected in the Company’s condensed consolidated financial statements for the nine months ended September 30, 2022 and 2021 related to these indemnifications.

The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification agreements.

Product Warranties

The Company warrants certain of its products to be free of defects generally for a period of three years. The Company estimates its warranty costs based on historical warranty claim experience and includes such costs in cost of net revenues. Warranty costs were not material for the nine months ended September 30, 2022 and 2021.

Legal Matters

The Company is not a party to any legal proceeding that the Company believes is likely to have a material adverse effect on its condensed consolidated financial position or results of operations. From time to time the Company may be subject to legal proceedings and claims in the ordinary course of business. These claims, even if not meritorious, could result in the expenditure of significant financial resources and diversion of management efforts.

Note 7. Business Segments, Concentration of Credit Risk and Significant Customers

The Company determined its reporting units in accordance with ASC 280, Segment Reporting (ASC 280). Management evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines if the segments are economically similar and, if so, the operating segments are aggregated.

Management has determined that the Company has one consolidated operating segment. The Company’s reporting segment reflects the manner in which its chief operating decision maker reviews results and allocates resources. The Company’s reporting segment meets the definition of an operating segment and does not include the aggregation of multiple operating segments.

The Company recognized revenue from shipments of product, licensing of its technologies and performance of services to customers by geographical location as follows (in thousands):

|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 30, |  |  | September 30, |
|  | 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
North America |  | $ | 1,918 |  |  | $ | 984 |  |  | $ | 7,158 |  |  | $ | 1,145 |
Hong Kong |  |  | 447 |  |  |  | 1,027 |  |  |  | 1,328 |  |  |  | 2,057 |
Taiwan |  |  | 131 |  |  |  | (2 | ) |  |  | 646 |  |  |  | 586 |
Japan |  |  | 368 |  |  |  | — |  |  |  | 905 |  |  |  | — |
Rest of world |  |  | 430 |  |  |  | 9 |  |  |  | 944 |  |  |  | 28 |
Total net revenue |  | $ | 3,294 |  |  | $ | 2,018 |  |  | $ | 10,981 |  |  | $ | 3,816 |

21

Customers who accounted for at least 10% of total net revenue were:

|  | Three Months Ended |  | Nine Months Ended
|  | September 30, |  | September 30,
|  | 2022 |  | 2021 |  | 2022 |  | 2021
Customer A |  | 24% |  | * |  | 24% |  | *
Customer B |  | 22% |  | 14% |  | 28% |  | *
Customer C |  | 14% |  | 45% |  | 12% |  | 48%
Customer D |  | * |  | * |  | * |  | 15%
Customer E |  | * |  | 33% |  | * |  | 18%

* | Represents less than 10%

As of September 30, 2022, two customers accounted for 60% of accounts receivable, and the Company recorded a provision for doubtful accounts of $683,000 against one of the customer’s receivables. Three customers accounted for 96% of accounts receivable as of December 31, 2021.

Note 8. Income Tax Provision

The Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company’s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized.

The Company files U.S. federal and state and foreign income tax returns in jurisdictions with varying statutes of limitations. All tax returns from 2015 to 2020 may be subject to examination by the Internal Revenue Service, California and other states. Returns filed in foreign jurisdictions may be subject to examination for the years 2011 to 2020. As of September 30, 2022, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.

Note 9. Stock-Based Compensation

Common Stock Equity Plans

In 2010, the Company adopted the 2010 Equity Incentive Plan and later amended it in 2014, 2017 and 2018 (the Amended 2010 Plan). The Amended 2010 Plan was terminated in August 2019 and remains in effect as to outstanding equity awards granted prior to the date of expiration. No new awards may be made under the Amended 2010 Plan.

In August 2019, the Company’s stockholders approved the 2019 Stock Incentive Plan (the 2019 Plan), and it replaced the Amended 2010 Plan. The 2019 Plan authorizes the board of directors or the compensation committee of the board of directors to grant a broad range of awards including stock options, stock appreciation rights, restricted stock, performance-based awards, and restricted stock units. Under the 2019 Plan, 182,500 shares were initially reserved for issuance.

In November 2021, in connection with the approval of the Arrangement, the Company’s stockholders approved an amendment increasing the number of shares reserved for issuance under the 2019 Plan by 3,106,937 shares.

Under the 2019 Plan, the term of all incentive stock options granted to a person who, at the time of grant, owns stock representing more than 10% of the voting power of all classes of the Company’s stock may not exceed five years. The exercise price of stock options granted under the 2019 Plan must be at least equal to the fair market value of the shares on the date of grant. Generally, awards under the 2019 Plan will vest over a three to four-year period, and options will have a term of 10 years from the date of grant. In addition, the 2019 Plan provides for automatic acceleration of vesting for options granted to non-employee directors upon a change of control of the Company.

In connection with the Arrangement, the Company assumed the Peraso Technologies Inc. 2009 Share Option Plan (the 2009 Plan) and all outstanding options granted pursuant to the terms of the 2009 Plan. Each outstanding, unexercised and unexpired option under the 2009 Plan, whether vested or unvested, was assumed by the Company and converted into options to purchase shares of the Company’s common stock and became exercisable by the holder of such option in accordance with its terms, with (i) the number of shares of common stock subject to each option multiplied by the Exchange Ratio and (ii) the per share exercise price upon the exercise of each option divided by the Exchange Ratio. In connection with the Arrangement, no further awards will be made under the 2009 Plan.

The 2009 Plan, the Amended 2010 Plan and the 2019 Plan are referred to collectively as the “Plans.”

22

Stock-Based Compensation Expense

The Company reflected compensation costs of $3.4 million and $3.5 million related to the vesting of stock options during the nine-month periods ended September 30, 2022 and 2021, respectively. At September 30, 2022, the unamortized compensation cost was approximately $8.9 million related to stock options and is expected to be recognized as expense over a weighted average period of approximately 2.3 years. The Company reflected compensation costs of $1.0 million and zero related to the vesting of restricted stock options during the nine months ended September 30, 2022 and 2021, respectively. The unamortized compensation cost at September 30, 2022 was $2.3 million related to restricted stock units and is expected to be recognized as expense over a weighted average period of approximately 2.3 years.

Valuation Assumptions and Expense Information for Stock-Based Compensation

There were no stock options granted or exercised during the nine months ended September 30, 2022. There were no stock options granted and stock options were exercised for 452 shares of common stock during the nine months ended September 30, 2021.

Common Stock Options and Restricted Stock

The term of all incentive stock options granted to a person who, at the time of grant, owns stock representing more than 10% of the voting power of all classes of the Company’s stock may not exceed five years. The exercise price of stock options granted under the 2019 Plan must be at least equal to the fair market value of the shares on the date of grant. Generally, options granted under the 2019 Plan will vest over a three to four-year period and have a term of 10 years from the date of grant. In addition, the 2019 Plan provides for automatic acceleration of vesting for options granted to non-employee directors upon a change of control (as defined in the 2019 Plan) of the Company.

The following table summarizes the activity in the shares available for grant under the Plans during the nine months ended September 30, 2022 (in thousands, except exercise price):

|  |  |  |  | Options Outstanding |
|  |  |  |  |  |  |  |  | Weighted |
|  | Shares |  |  |  |  |  | Average |
|  | Available |  | Number of |  |  | Exercise |
|  | for Grant |  | Shares |  |  | Prices |
Balance as of December 31, 2021 |  |  | 3,024 |  |  | 1,558 |  |  | $ | 3.49 |
Options cancelled |  |  | — |  |  | (13 | ) |  | $ | 10.98 |
Balance as of March 31, 2022 |  |  | 3,024 |  |  | 1,545 |  |  | $ | 3.43 |
RSUs granted |  |  | (1,511 | ) |  | — |  |  | $ | - |
RSUs cancelled and returned to the Plan |  |  | 43 |  |  | — |  |  | $ | - |
Options cancelled |  |  | — |  |  | (8 | ) |  | $ | 2.63 |
Balance as of June 30, 2022 |  |  | 1,556 |  |  | 1,537 |  |  | $ | 3.43 |
RSUs granted |  |  | (67 | ) |  | — |  |  | $ | - |
RSUs cancelled and returned to the Plan |  |  | 103 |  |  | — |  |  | $ | - |
Options cancelled |  |  | — |  |  | (23 | ) |  | $ | 2.57 |
Balance as of September 30, 2022 |  |  | 1,592 |  |  | 1,514 |  |  | $ | 3.39 |

23

A summary of RSU activity under the Plans is presented below (in thousands, except for fair value):

|  |  |  |  |  | Weighted |
|  |  |  |  |  | Average |
|  | Number of |  |  | Grant-Date |
|  | Shares |  |  | Fair Value |
Non-vested shares as of December 31, 2021 |  |  | 88 |  |  | $ | 4.84 |
Vested |  |  | (13 | ) |  | $ | 3.70 |
Non-vested shares as of March 31, 2022 |  |  | 75 |  |  | $ | 5.67 |
Granted |  |  | 1,511 |  |  |  | — |
Vested |  |  | (271 | ) |  | $ | 2.49 |
Cancelled |  |  | (12 | ) |  |  | — |
Non-vested shares as of June 30, 2022 |  |  | 1,303 |  |  | $ | 2.28 |
Granted |  |  | 67 |  |  |  | — |
Vested |  |  | (38 | ) |  | $ | 2.45 |
Cancelled |  |  | (103 | ) |  |  | — |
Non-vested shares as of September 30, 2022 |  |  | 1,229 |  |  | $ | 2.27 |

The following table summarizes significant ranges of outstanding and exercisable options as of September 30, 2022 (in thousands, except contractual life and exercise price):

|  | Options Outstanding |  |  | Options Exercisable |
|  |  |  |  |  | Weighted |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  | Average |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  | Remaining |  |  | Weighted |  |  |  |  |  |  | Weighted |  |  |  |  |
|  |  |  |  |  | Contractual |  |  | Average |  |  |  |  |  |  | Average |  |  | Aggregate |
|  | Number |  |  | Life |  |  | Exercise |  |  | Number |  |  | Exercise |  |  | Intrinsic |
Range of Exercise Price |  | Outstanding |  |  | (in Years) |  |  | Price |  |  | Exercisable |  |  | Price |  |  | value |
$1.57 - $14.99 |  |  | 1,502 |  |  |  | 7.89 |  |  | $ | 2.65 |  |  |  | 865 |  |  | $ | 2.52 |  |  | $ | 10 |
$15.00 - $25.59 |  |  | 5 |  |  |  | 0.98 |  |  | $ | 17.12 |  |  |  | 5 |  |  | $ | 17.12 |  |  | $ | — |
$25.60 - $143.99 |  |  | 1 |  |  |  | 3.89 |  |  | $ | 101.27 |  |  |  | 1 |  |  | $ | 101.27 |  |  | $ | — |
$144.00 - $409.99 |  |  | 5 |  |  |  | 3.74 |  |  | $ | 144.00 |  |  |  | 5 |  |  | $ | 144.00 |  |  | $ | — |
$410.00 - $924.00 |  |  | 1 |  |  |  | 1.95 |  |  | $ | 410.00 |  |  |  | 1 |  |  | $ | 410.00 |  |  | $ | — |
$1.57 - $924.00 |  |  | 1,514 |  |  |  | 7.85 |  |  | $ | 3.39 |  |  |  | 877 |  |  | $ | 3.81 |  |  | $ | 10 |

Note 10. Equity

Warrants

As of September 30, 2022, the Company had the following warrants outstanding (share amounts in thousands):

Type |  | Number of Shares |  |  | Exercise Price |  |  | Expiration
Common stock |  |  | 33 |  |  | $ | 47.00 |  |  | January 2023
Common stock |  |  | 101 |  |  | $ | 2.40 |  |  | October 2023

24

Note 11. Debt

Loan Facilities

On November 30, 2020, the Company entered into a loan agreement (the SRED Financing) to raise funds against the Company’s present and after acquired personal property. On February 5, 2021, March 5, 2021 and September 17, 2021 the Company raised additional funds from the second, third and fourth draws under the SRED financing of $274,715 (CDN$350,000), $274,715 (CDN$350,000) and $745,655 (CDN$950,000) respectively, totaling year to date gross proceeds of $1,295,085 (CDN$1,650,000) net of financing fees of $32,770 (CDN$41,750). Each borrowing carried an interest rate of 1.6% per month, compounded monthly (20.98%). The SRED financing was sanctioned against the Company’s SRED tax credit refund.

The first, second and third draws, including interest of $136,900 (CDN$174,417), were repaid through proceeds from the Company’s tax credit refund of $1,093,230 (CDN$1,392,831) received in August 2021, and the balance of $184,558 (CDN$ 235,132) was paid from the fourth draw. The remaining loan balance, including interest, of $816,964 (CDN$1,044,177) was repaid on December 16, 2021.

Interest expense of $870,212 for the three months ended September 30, 2021 consisted of i) $625,913 of amortization of debt discount, ii) $212,971 of interest expense on convertible debt, which was outstanding and retired in 2021, and iii) $31,328 of interest expense on the SRED financing. Interest expense of $2,170,059 for the nine months ended September 30, 2021 consisted of i) $1,510,368 of amortization of debt discount, ii) $522,274 of interest expense on convertible debt, which was outstanding and retired in 2021, and iii) $137,417 of interest expense on the SRED financing.

Note 12. Related Party Transactions

A family member of one of the Company’s executive officers serves as a consultant to the Company. During the nine months ended September 30, 2022 and 2021, the Company paid approximately $126,800 and $153,100, respectively, to the consultant. Additionally, a family member of one of the Company’s executive officers is an employee of the Company. During the nine months ended September 30, 2022, the Company paid approximately $127,500 to the employed family member, which includes the aggregate grant date fair value, as determined pursuant to FASB ASC Topic 718, of an RSU awarded in April 2022. During the nine months ended September 30, 2021, the Company paid approximately $69,000 to the employed family member.

Note 13. License and Asset Sale Transaction

On August 5, 2022, the Company entered into a Technology License and Patent Assignment Agreement (the Intel Agreement) with Intel Corporation (Intel), pursuant to which Intel: (i) licensed from the Company, on an exclusive basis, certain software and technology assets related to the Company’s Stellar packet classification intellectual property, including its graph memory engine technology, and any roadmap variant, in the form existing as of the date of the Agreement (the Licensed Technology); (ii) acquired from the Company certain patent applications and patents owned by the Company; and (iii) assumed a professional services agreement, dated March 24, 2020, between Fabulous Inventions AB (Fabulous) and the Company (the Fabulous Agreement), pursuant to which, among other things, the Company licensed from Fabulous certain technology incorporated into the Licensed Technology.

As consideration for the Company to enter into the Agreement, Intel agreed to pay the Company $3,062,500 at the closing of the transaction (the Closing) and $437,500 (the Holdback) upon the satisfaction by the Company, as mutually agreed upon by the parties in good faith, of certain release criteria set forth in the Agreement relating to various due diligence activities of Intel regarding the Licensed Technology (the Release Criteria). Intel and the Company agreed to work together in good faith so as to ensure that the Release Criteria is satisfied by the Company no later than six months following the Closing.

The Company determined that the license and asset sale did not qualify as a sale of a business, but as a sale of a non-financial asset, with the resultant gain recorded as income from operations in accordance with ASC 610-20, Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets. During the three months ended September 30, 2022, the Company recognized a $2.6 million gain on this transaction, net of transaction costs, which was recorded as a reduction of operating expenses in the condensed consolidated statements of operations and comprehensive loss. Any gain related to the Holdback will be recorded when the Release Criteria have been satisfied, which is expected to be within six months of August 5, 2022.

25

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the accompanying condensed consolidated financial statements and notes included in this report. This Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which include, without limitation, statements about the market for our technology, our strategy, competition, expected financial performance and capital raising effort., the impacts of COVID-19 on our business, the effects of the Russia/Ukraine conflict, and inflation, which could cause customers to delay or reduce purchases of our products or delay payments to us, which would adversely affect our financial results, including cash flows, and other aspects of our business identified in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2022 and in other reports that we file from time to time with the Securities and Exchange Commission. Any statements about our business, financial results, financial condition and operations contained in this Form 10-Q that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “projects” or similar expressions are intended to identify forward-looking statements. Our actual results could differ materially from those expressed or implied by these forward-looking statements as a result of various factors, including the risk factors described under Item 1A of our annual report on Form 10-K for the year ended December 31, 2021 and the risk factors described below under Item 1A of this Form 10-Q. We undertake no obligation to update publicly any forward-looking statements for any reason, except as required by law, even as new information becomes available or events occur in the future.

Overview

We were formerly known as MoSys, Inc. (MoSys) and were incorporated in California in 1991 and reincorporated in Delaware in 2000. On September 14, 2021, we and our subsidiaries, 2864552 Ontario Inc. and 2864555 Ontario Inc., entered into an Arrangement Agreement (the Arrangement Agreement) with Peraso Technologies Inc. (Peraso Tech), a corporation existing under the laws of the province of Ontario, to acquire all of the issued and outstanding common shares of Peraso Tech (the Peraso Shares), including those Peraso Shares to be issued in connection with the conversion or exchange of secured convertible debentures and common share purchase warrants of Peraso Tech, as applicable, by way of a statutory plan of arrangement (the Arrangement) under the Business Corporations Act (Ontario). On December 17, 2021, following the satisfaction of the closing conditions set forth in the Arrangement Agreement, the Arrangement was completed and the Company changed its name to “Peraso Inc.” and began trading on the Nasdaq Stock Market under the symbol “PRSO.”

For accounting purposes, the legal subsidiary, Peraso Tech, has been treated as the accounting acquirer and we, the legal parent, have been treated as the accounting acquiree. The transaction has been accounted for as a reverse acquisition in accordance with Financial Accounting Standards Board Accounting Standards Codification (ASC) No. 805, Business Combinations. Accordingly, the financial condition and results of operations discussed herein are a continuation of Peraso Tech’s financial results prior to December 17, 2021 and exclude the financial results of us prior to December 17, 2021. See Note 2 to the condensed consolidated financial statements for additional disclosure.

Our strategy and primary business objective is to be a profitable, IP-rich, fabless semiconductor company offering integrated circuits (ICs), modules and related non-recurring engineering services. We specialize in the development of mmWave semiconductors, primarily in the 60 GHz spectrum band for 802.11ad/ay compliant devices and in the 28/39 GHz spectrum bands for 5G-compliant devices. We derive our revenue from selling semiconductor devices, as well as modules based on using those mmWave semiconductor devices. We have pioneered a high-volume mmWave production test methodology using standard low cost production test equipment. It has taken us several years to refine performance of this production test methodology, and we believe this places us in a leadership position in addressing operational challenges of delivering mmWave products into high-volume markets. During 2021, we augmented our business model and began selling complete mmWave modules. The primary advantage provided by a module is the silicon and the antenna are integrated into a single device. A differentiating characteristic of mmWave technology is that the radio frequency amplifiers must be as close as possible to the antenna to minimize loss, and, by providing a module, we can guarantee the performance of the amplifier/antenna interface.

We also have a memory product line, marketed under the Accelerator Engine name, which includes our Bandwidth Engine IC products, which integrate our proprietary, 1T-SRAM high-density embedded memory and a highly-efficient, serial interface protocol resulting in a monolithic memory IC solution optimized for memory bandwidth and transaction access performance. As we are not developing new memory products, from a product development perspective, we continue to leverage our current technologies and core competencies to expand our product offerings without incurring significant additional research and development (R&D) expenses.

We incurred net losses of approximately $16.6 million for the nine months ended September 30, 2022 and $10.9 million for the year ended December 31, 2021, and we had an accumulated deficit of approximately $133.8 million as of September 30, 2022. These and prior year losses have resulted in significant negative cash flows and historically have required us to raise substantial amounts of additional capital. We expect to continue to incur operating losses and will need to increase revenues substantially beyond levels that we have attained in the past in order to generate sustainable operating profit and sufficient cash flows to continue doing business without raising additional capital from time to time.

26

COVID-19 and Macroeconomic Factors

The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in-place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on our operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by the U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of our control, and cannot be predicted.

Since March 2020, certain jurisdictions in which we operate have issued ’shelter-in-place” orders. We have complied with these orders and, when such orders were in place, minimized business activities at our facilities. We have implemented a teleworking policy for our employees and contractors to reduce on-site activity.

We believe that as the COVID-19 pandemic evolves, the direct and indirect impacts of the pandemic on global macroeconomic conditions, as well as conditions specific to us, are becoming more difficult to isolate or quantify. In addition, these direct and indirect factors can make it difficult to isolate and quantify the portion of our costs that are a direct result of the pandemic and costs arising from factors that may have been influenced by the pandemic, such as supply chain constraints, rising inflation, and recessionary fears. We expect these factors and their effects on our operations may persist for a longer period, even after the COVID-19 pandemic has subsided. We continue to closely monitor impacts, especially to customer programs and our supply chain. We are working internally and with suppliers on programs (i.e., new production flows, etc.) to allow us to increase our peak throughput to better handle unplanned disruptions to our supply chain. To date, we have not experienced a material impact on our cash flows, liquidity, capital resources, cash requirements, financial position, or results of operations, attributable to the global semiconductor supply chain disruption and inflation. We have experienced increased prices from our suppliers, and, for certain products, we have increased prices to our customers to mitigate the impacts, although to date in 2022 the impacts of these price increases have been minimal. We have and continue to experience longer lead times for certain components used to manufacture our products, and, therefore, and, in response, we have identified second and third sources for certain components used in our module products. Also, we have increased lead times for our customers. We have not experienced any issues over our product quality and product development activities, as we do not rely significantly on outside vendors to manage and perform these activities for us. We currently have not identified any current impacts of the supply chain disruption and inflation that will affect our future results, and it is difficult to differentiate whether higher prices are due to supply chain disruption, inflation or a mix of both.

While we believe that our operations personnel are currently in a position to meet expected customer demand levels in the coming quarters, we recognize that unpredictable events could create difficulties in the months ahead. We may not be able to address these difficulties in a timely manner, which could negatively impact our business, results of operations, financial condition and cash flows.

The continued spread of COVID-19 has also led to disruption and volatility in the global capital markets. The Russian invasion of Ukraine in February 2022 has led to further economic disruptions. Mounting inflationary cost pressures and recessionary fears have negatively impacted the global economy. During the third quarter of 2022, the U.S. Federal Reserve continued to aggressively address elevated inflation by increasing interest rates. The U.S. Federal Reserve increased interest rates by 75 basis points in each of its meetings held in July, September and November 2022, with an additional increase forecasted for December 2022 as inflation remains elevated. Given current market conditions, we may be unable to access the capital markets, and additional capital may only be available to us on terms that could be significantly detrimental to our existing stockholders and to our business.

For additional information on risks that could impact our future results, please refer to “Risk Factors” in Part II, Item 1A. of this quarterly report on Form 10-Q.

Sources of Revenue

Product revenue

Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied. The majority of our contracts have a single performance obligation to transfer products. Accordingly, we recognize revenue when title and risk of loss have been transferred to the customer, generally at the time of shipment of products. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products and is generally based upon a negotiated, formula, list or fixed price. We sell our products both directly to customers and through distributors generally under agreements with payment terms typically 60 days or less.

We may record an estimated allowance, at the time of shipment, for future returns and other charges against revenue consistent with the terms of sale.

27

Royalty and other

Our licensing contracts typically provide for royalties based on the licensee’s use of our memory technology in its currently shipping commercial products. We estimate its royalty revenue in the calendar quarter in which the licensee uses the licensed technology. Payments are received in the subsequent quarter. We also generate revenue from licensing our technology. We recognize license fees as revenue at the point of time when the control of the license has been transferred and we have no continuing performance obligations to the customer.

Engineering services revenue

Engineering and development contracts with customers generally contain a single performance obligation that is delivered over time. Revenue is recognized using an output method that is consistent with the satisfaction of the performance obligation as a measure of progress.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The preparation of these condensed consolidated financial statements requires us to make certain estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis we make these estimates based on our historical experience and on assumptions that we consider reasonable under the circumstances. Actual results may differ from these estimates and reported results could differ under different assumptions or conditions. Our significant accounting policies and estimates are disclosed in Note 1 of the “Notes to Consolidated Financial Statements” in our annual report on Form 10-K for the year ended December 31, 2021. As of September 30, 2022, there have been no material changes to our significant accounting policies and estimates.

Reclassifications

We previously classified intangible asset amortization expense related to the developed technology and customer relationships intangibles within research and development expenses (R&D) in our condensed consolidated statements of operations and comprehensive loss. Amortization expense on the developed technology intangible asset is now classified within cost of net revenue, and amortization expense on customer relationships is now classified in selling, general and administrative expenses (SG&A). Prior period amounts have been conformed to the current period presentation. See Notes 1 and 5 to the condensed consolidated financial statements for a discussion of the reclassifications.

Results of Operations

Net Revenue

|  | September 30, |  |  | Change |
|  | 2022 |  |  | 2021 |  |  | 2021 to 2022 |
|  | (dollar amounts in thousands) |
Product -three months ended |  | $ | 3,060 |  |  | $ | 1,389 |  |  | $ | 1,671 |  |  |  | 120 | %
Percentage of total net revenue |  |  | 93 | % |  |  | 69 | % |  |  |  |  |  |  |  |
Product -nine months ended |  | $ | 10,384 |  |  | $ | 3,016 |  |  | $ | 7,368 |  |  |  | 244 | %
Percentage of total net revenue |  |  | 95 | % |  |  | 79 | % |  |  |  |  |  |  |  |

The following table details revenue by product category for the three and nine months ended September 30, 2022 (in thousands):

|  | For the three months ended September 30, |  |  | For the nine months ended September 30, |  |
Product category |  | 2022 |  |  | 2021 |  |  | change |  |  | 2022 |  |  | 2021 |  |  | change |  |
Memory ICs |  | $ | 1,748 |  |  | $ | — |  |  | $ | 1,748 |  |  | $ | 5,528 |  |  | $ | — |  |  | $ | 5,528 |  |
mmWave ICs |  |  | 533 |  |  |  | 1,033 |  |  |  | (500 | ) |  |  | 1,699 |  |  |  | 2,651 |  |  |  | (952 | ) |
mmWave modules |  |  | 779 |  |  |  | 292 |  |  |  | 487 |  |  |  | 3,139 |  |  |  | 292 |  |  |  | 2,847 |  |
mmWave other products |  |  | — |  |  |  | 64 |  |  |  | (64 | ) |  |  | 18 |  |  |  | 73 |  |  |  | (55 | ) |
|  | $ | 3,060 |  |  | $ | 1,389 |  |  | $ | 1,671 |  |  | $ | 10,384 |  |  | $ | 3,016 |  |  | $ | 7,368 |  |

28

Product revenue increased for the three months ended September 30, 2022 compared with the same period of 2021 primarily due to the increase in the memory IC sales volumes due to the acquisition of this product line in December 2021 and the increase of the mmWave module sales volumes due to the roll-out of this product line in August 2021. As discussed elsewhere in this Report, for reverse-acquisition accounting purposes, Peraso Tech, was treated as the accounting acquirer, and MoSys was treated as the accounting acquiree. Accordingly, the results of operations discussed herein are a continuation of Peraso Tech’s historical financial results and exclude the results of operations of MoSys prior to December 17, 2021. The increase in memory IC sales volumes, which was due to the acquisition of this product line, resulted in a $1.7 million increase to revenue for the three months ended September 30, 2022, as compared to the prior year due to a 100% increase in sales volumes in 2022. Additionally, we began selling our mmWave module products during the second half of 2021, representing a 119% increase in sales volumes and an additional $0.5 million in revenue for the three months ended September 30, 2022. We have initiated price increases on certain of our module products in 2022. However, through September 30, 2022, we had not realized any material increase in revenue as a result of those price increases.

Product revenue increased for the nine months ended September 30, 2022 compared with the same period of 2021 primarily due to increase in the memory IC sales volumes due to the acquisition of this product line in December 2021 and the increase of mmWave module sales volumes due to the roll-out of this new product line in the second half of 2021. The increase in memory IC sales volumes resulted in a $5.5 million increase in revenues for the nine months ended September 30, 2022 as compared to prior year due to a 100% increase in sales volumes. Additionally, we began selling our mmWave module products during the second half of 2021 and realized a 100% increase in sales volumes in 2022, which contributed $2.8 million of increased revenue for the nine months ended September 30, 2022. We initiated price increases on certain of our module products in 2022. However, through September 30, 2022, we had not realized any material increase in revenue as a result of those price increases. These revenue increases were partially offset by a decrease of $1.0 million in sales of our mmWave IC products due to a 39% reduction in volumes shipped during the nine months ended September 30, 2022, compared with the same period in 2021. Although, stand-alone mmWave IC volumes decreased, shipments of our mmWave modules that include the mmWave ICs have increased, and each module we ship includes our mmWave ICs. We began shipping modules, which include our mmWave IC in a chipset with an antenna, as it provides an integrated solution that we believe can shorten our revenue cycle by enabling our customers to accelerate time to production. In addition, we generate higher revenue from the sale of modules compared to sales of stand-alone ICs. Going forward, we expect sales of our mmWave ICs on a stand-alone basis to decline as a percentage of total product revenue, as we expect sales of our modules to be our primary source of revenue growth.

We expect revenues to increase for the remainder of 2022 and in 2023, as we expect increased sales of our mmWave products, including the benefits of price increases implemented in 2022, and will experience a full-year contribution of revenues from our memory products. We expect sales of our memory products to increase from a volume and revenue perspective over the next 12 months. However, our memory products have been in production since 2014, and, given that we have not developed new products, the long-term outlook for these products is uncertain. We have implemented modest price increases on our memory products that we expect to begin taking effect in the first half of 2023, and we expect these price increases to contribute to revenue growth in 2023. We expect sales of our mmWave modules to increase from a volume and revenue perspective over the next 12 months, as our primary sales focus is on obtaining new module customers. Our lead module customer has provided purchase orders and forecasts, which support our expected increases in volume and revenue from module shipments. In addition, we expect meaningful contribution in 2023 from price increases that we implemented in 2022 on our module products.

.

|  | September 30, |  |  | Change |
|  | 2022 |  |  | 2021 |  |  | 2021 to 2022 |
|  | (dollar amounts in thousands) |
Royalty and other -three months ended |  | $ | 234 |  |  | $ | 629 |  |  | $ | (395 | ) |  |  | (63 | )%
Percentage of total net revenue |  |  | 7 | % |  |  | 31 | % |  |  |  |  |  |  |  |
Royalty and other -nine months ended |  | $ | 597 |  |  | $ | 800 |  |  | $ | (203 | ) |  |  | (25 | )%
Percentage of total net revenue |  |  | 5 | % |  |  | 21 | % |  |  |  |  |  |  |  |

Royalty and other includes royalty, non-recurring engineering, services and licenses revenues. The decrease in royalty and other revenue for the three and nine months ended September 30, 2022 compared with the same period of 2021 was primarily due to a decrease in non-recurring engineering services revenue related to our mmWave technology, partially offset by full three and nine-month contributions of royalty revenues from licensees of our memory technology. As the reverse acquisition occurred on December 17, 2021, the results of operations for the three and nine months ended September 30, 2021 exclude all royalty revenue from licensing of memory technology.

29

Cost of Net Revenue and Gross Profit

|  | September 30, |  |  | Change |
|  | 2022 |  |  | 2021 |  |  | 2021 to 2022 |
|  | (dollar amounts in thousands) |
Cost of net revenue -three months ended |  | $ | 2,000 |  |  | $ | 919 |  |  | $ | 1,081 |  |  |  | 118 | %
Percentage of total net revenue |  |  | 61 | % |  |  | 46 | % |  |  |  |  |  |  |  |
Cost of net revenue -nine months ended |  | $ | 6,747 |  |  | $ | 1,973 |  |  | $ | 4,774 |  |  |  | 242 | %
Percentage of total net revenue |  |  | 61 | % |  |  | 52 | % |  |  |  |  |  |  |  |

|  | September 30, |  |  | Change |
|  | 2022 |  |  | 2021 |  |  | 2021 to 2022 |
|  | (dollar amounts in thousands) |
Gross profit -three months ended |  | $ | 1,294 |  |  | $ | 1,099 |  |  | $ | 195 |  |  |  | 18 | %
Percentage of total net revenue |  |  | 39 | % |  |  | 54 | % |  |  |  |  |  |  |  |
Gross profit -nine months ended |  | $ | 4,234 |  |  | $ | 1,843 |  |  | $ | 2,391 |  |  |  | 130 | %
Percentage of total net revenue |  |  | 39 | % |  |  | 48 | % |  |  |  |  |  |  |  |

Cost of net revenue is primarily comprised of direct and indirect costs related to the sale of our products, including amortization of intangible assets and depreciation of production-related fixed assets.

Cost of net revenue increased for the three and nine months ended September 30, 2022 when compared with the same period in 2021, primarily due to increased shipment volumes of our LineSpeed and Bandwidth Engine IC and mmWave module products. Our module products have higher cost of goods sold per unit and generate lower gross profit margin than our IC products.

Gross profit increased for the three and nine months ended September 30, 2022 compared with the same period of 2021 due to the increased product shipments. The decrease in our gross profit margin for the three and nine months ended September 30, 2022 compared with the prior year periods was primarily attributable to the increased volume shipments of our mmWave modules, which carry lower gross margins than our IC products.

Research and Development

|  | September 30, |  |  | Change |
|  | 2022 |  |  | 2021 |  |  | 2021 to 2022 |
|  | (dollar amounts in thousands) |
R&D -three months ended |  | $ | 4,509 |  |  | $ | 2,696 |  |  | $ | 1,813 |  |  |  | 67 | %
Percentage of total net revenue |  |  | 137 | % |  |  | 134 | % |  |  |  |  |  |  |  |
Research and development -nine months ended |  | $ | 15,636 |  |  | $ | 8,375 |  |  | $ | 7,261 |  |  |  | 87 | %
Percentage of total net revenue |  |  | 142 | % |  |  | 219 | % |  |  |  |  |  |  |  |

Our R&D expenses include costs related to the development of our products. We expense R&D costs as they are incurred.

The increase for the three months ended September 30, 2022 compared with the same period of 2021 was primarily due to the inclusion of a full three months of expenses of $0.9 million related to the former operations of MoSys, amortization of acquired intangible assets from the reverse acquisition of $0.5 million, which closed on December 17, 2021, for the three and nine months ended September 30, 2022 and recognition of $0.5 million of Canadian government refundable tax credits and wage and rent subsidies during the first nine months of 2021 that reduced operating expenses.

The increase for the nine months ended September 30, 2022 compared with the same period of 2021 was primarily due to the inclusion of a full nine months of expenses of $3.8 million related to the former operations of MoSys, amortization of acquired intangible assets from the reverse acquisition of $1.5 million, which closed on December 17, 2021, and recognition of $1.8 million of Canadian government refundable tax credits and wage and rent subsidies during the first nine months of 2021 that reduced operating expenses.

We expect that total R&D expenses will increase in 2022 compared with 2021, as we will include the operations related to MoSys and increased development of our mmWave products and technologies, including our new 5G mmWave products. In addition, we do not expect to receive any Canadian government subsidies in 2022 that would reduce our R&D expenses.

30

Selling, General and Administrative

|  | September 30, |  |  | Change |
|  | 2022 |  |  | 2021 |  |  | 2021 to 2022 |
|  | (dollar amounts in thousands) |
SG&A -three months ended |  | $ | 3,353 |  |  | $ | 1,746 |  |  | $ | 1,607 |  |  |  | 92 | %
Percentage of total net revenue |  |  | 102 | % |  |  | 87 | % |  |  |  |  |  |  |  |
SG&A -nine months ended |  | $ | 8,938 |  |  | $ | 4,852 |  |  | $ | 4,086 |  |  |  | 84 | %
Percentage of total net revenue |  |  | 81 | % |  |  | 127 | % |  |  |  |  |  |  |  |

SG&A expenses consist primarily of personnel and related overhead costs for sales, marketing, finance, human resources and general management and amortization of intangible assets.

The increase for the three months ended September 30, 2022 compared with the same period of 2021 was primarily due to the inclusion of $1.4 million of expense, which represented the inclusion of a full three months of expenses related to related to the former operations of MoSys, as a result of the reverse acquisition that closed in December 2021. The increases were partially offset by a $0.5 million decrease in costs incurred during the three months ended September 30, 2021 related to the reverse acquisition.

The increase for the three and nine months ended September 30, 2022 compared with the same period of 2021 was primarily due to the inclusion of $4.2 million of expense, which represented the inclusion of a full nine months of expenses related to related to the former operations of MoSys, and recognition of Canadian government wage and rent subsidies during the first nine months of 2021 that reduced operating expenses. The increases were partially offset by a $1.1 million decrease in costs incurred during the nine months ended September 30, 2021 related to the reverse acquisition.

We expect that total SG&A expenses will increase in 2022 compared with 2021, as we will include the operations related to MoSys, and, in addition, we do not expect to receive any Canadian government subsidies in 2022 that would reduce our R&D expenses.

Interest expense

Interest expense incurred during the nine months ended September 30, 2021 related to our convertible debt and loans payable, which were repaid and/or converted into equity during 2021.

Liquidity and Capital Resources; Changes in Financial Condition

Cash Flows

As of September 30, 2022, we had cash, cash equivalents and investments of $3.9 million and working capital of $9.0 million.

Net cash used in operating activities was $13.4 million for the first nine months of 2022, which primarily resulted from our net loss of $17.8 million and $3.1 million in net changes in assets and liabilities, partially offset by non-cash charges of $2.3 million of depreciation and amortization, $4.4 million of stock based compensation, $0.7 million of allowance for doubtful accounts and $0.1 million for other non-cash items. The changes in assets and liabilities primarily related to the timing of accounts receivable collections, purchases of inventory and other vendor payables and prepayments.

Net cash used in operating activities was $7.1 million for the first nine months of 2021, which primarily resulted from our net loss of $13.4 million and a $0.1 million other non-cash items, which was offset by non-cash charges of $3.5 million of stock-based compensation, $0.8 million of depreciation and amortization expenses, $1.5 million amortization of debt discount, and $0.6 million of accrued interest. The changes in assets and liabilities primarily related to the timing of accounts receivable collections and other vendor payables and prepayments.

Net cash provided by investing activities of $10.4 million for the nine months ended September 30, 2022 represented $11.5 million in proceeds from maturities of short-term investments, partially offset by $0.5 million purchases of short and long-term investments and $0.6 million of purchases of property and equipment. Net cash used in investing activities for the nine months ended September 30, 2021 represented approximately $57,000 of purchases of property and equipment and $95,000 of intangible assets.

Net cash used in financing activities for the nine months ended September 30, 2022 consisted of taxes paid to net share settle equity awards.

Net cash provided by financing activities for the nine months ended September 30, 2021 consisted of net proceeds received from an unsecured loan.

31

Our future liquidity and capital requirements are expected to vary from quarter-to-quarter, depending on numerous factors, including:

| • | level of revenue;

| • | cost, timing and success of technology development efforts;

| • | inventory levels, as supply chain disruption has required us to maintain higher inventory levels and place purchase orders with our suppliers longer into the future, which exposes us to additional inventory risk;

| • | timing of product shipments, which may be impacted by supply chain disruptions;

| • | length of billing and collection cycles, which may be impacted in the event of a global recession or economic downturn;

| • | fabrication costs, including mask costs, of our ICs, currently under development;

| • | variations in manufacturing yields, material lead time and costs and other manufacturing risks;

| • | costs of acquiring other businesses and integrating the acquired operations; and

| • | profitability of our business.

As of September 30, 2022, we had outstanding accounts receivable of $1.6 million, which included $0.7 million collectible from WeLink Communications LLC (WeLink), a customer that represented 28% of our revenue for the nine months ended September 30, 2022. During the three months ended September 30, 2022, we had $1.1 million of product shipments to WeLink for which the revenue recognition criteria under ASC 606 had not been met. Accordingly, we deferred the cost of net revenue of $0.6 million associated with these shipments, and the amount deferred has been presented as deferred cost of net revenue in our condensed consolidated balance sheets.

Historically, we have collected all amounts due from WeLink, although generally not within contractual payment terms. As of September 30, 2022, we determined that an allowance for doubtful accounts of $0.7 million was warranted on the outstanding receivables from WeLink due to the delays in collecting from WeLink. The longer collection times have negatively impacted our liquidity and working capital. No assurances can be given that we will be able to collect the receivables from WeLink in a timely manner, if at all. Recognition of additional bad debt expense, further delays in collecting accounts receivable or our inability to recognize the deferred cost of net revenues could have a material adverse effect on our financial condition, cash flows and results of operations.

Going Concern - Working Capital

We incurred net losses of approximately $17.8 million for the nine months ended September 30, 2022 and $10.9 million for the year ended December 31, 2021, and we had an accumulated deficit of approximately $135.0 million as of September 30, 2022. These and prior year losses have resulted in significant negative cash flows and have required us to raise substantial amounts of additional capital. To date, we have primarily financed our operations through multiple offerings of common stock and issuance of convertible notes and loans to investors and affiliates.

We expect to continue to incur operating losses for the foreseeable future as we continue to secure new customers for and continue to invest in the development of our products, and we expect our cash expenditures to continue to exceed receipts for the foreseeable future, as our revenues will not be sufficient to offset our operating expenses.

We will need to increase revenues substantially beyond levels that we have attained in the past in order to generate sustainable operating profit and sufficient cash flows to continue doing business without raising additional capital from time to time. As a result of our expected operating losses and cash burn for the foreseeable future and recurring losses from operations, if we are unable to raise sufficient capital through additional debt or equity arrangements, there will be uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises substantial doubt as to our ability to continue as a going concern within one year from the date of issuance of these condensed consolidated financial statements. The condensed consolidated financial statements presented in Item 1 of this Report have been prepared assuming that we will continue as a going concern, and do not include any adjustments that might result from the outcome of this uncertainty. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions acceptable to us. We are currently seeking additional financing in order to meet our cash requirements for the foreseeable future. If the Company is unsuccessful in these efforts, it will need to implement cost reduction strategies, which could further affect

32

its near- and long-term business plan. These efforts may include, but are not limited to, reducing headcount and curtailing business activities. As further discussed in Note 11 to the condensed consolidated financial statements, in August 2022, we entered into an exclusive technology license and patent assignment agreement with Intel Corporation, under which we collected $3.1 million in August 2022 and expect to collect $0.4 million by early 2023. We expect this transaction to result in a reduction of operating expenses of approximately $2.7 million on annual basis.

If we were to raise additional capital through sales of our equity securities, our stockholders would suffer dilution of their equity ownership. If we engage in debt financing, we may be required to accept terms that restrict our ability to incur additional indebtedness, prohibit us from paying dividends, repurchasing our stock or making investments, and force us to maintain specified liquidity or other ratios, any of which could harm our business, operating results and financial condition. If we need additional capital and cannot raise it on acceptable terms, we may not be able to, among other things:

| • | develop or enhance our products;

| • | continue to expand our product development and sales and marketing organizations;

| • | acquire complementary technologies, products or businesses;

| • | expand operations, in the United States or internationally;

| • | hire, train and retain employees; or

| • | respond to competitive pressures or unanticipated working capital requirements.

Our failure to do any of these things could seriously harm our ability to execute our business strategy and may force us to curtail our existing operations.

Off-Balance Sheet Arrangements

We do not maintain any off-balance sheet arrangements or obligations that are reasonably likely to have a material current or future effect on our financial condition, results of operations, liquidity or capital resources.

Recent Accounting Pronouncements

See Note 1 to the condensed consolidated financial statements for a discussion of recently-issued accounting pronouncements.

33

ITEM 4. Controls and Procedures

Disclosure Controls and Procedures. Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based on this evaluation, our management concluded that, as of September 30, 2022, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting. During the nine months ended September 30, 2022, there was no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

ITEM 1. Legal Proceedings

The discussion of legal matters in Note 6 of the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this report under the heading “Legal Matters” is incorporated by reference in response to this Part II, Item 1.

ITEM 1A. Risk Factors

We face many significant risks in our business, some of which are unknown to us and not presently foreseen. These risks could have a material adverse impact on our business, financial condition and results of operations in the future. Other than as set forth below, there have been no material changes with respect to the risk factors disclosed under Item 1A of our annual report on Form 10-K for the year ended December 31, 2021, which we filed with the SEC on March 31, 2022.

We might not be able to continue as a going concern.

Our unaudited condensed consolidated financial statements as of September 30, 2022 have been prepared under the assumption that we will continue as a going concern for the next twelve months. As of September 30, 2022, we had cash, cash equivalents and investments of $3.9 million and an accumulated deficit of $135.0 million. We do not believe that our cash, cash equivalents and investments are sufficient to fund our operations for the next 12 months. We will need to increase revenues substantially beyond levels that we have attained in the past in order to generate sustainable operating profit and sufficient cash flows to continue doing business without raising additional capital from time to time. As a result of our expected operating losses and cash burn for the foreseeable future and recurring losses from operations, if we are unable to raise sufficient capital through additional debt or equity arrangements, there will be uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises substantial doubt as to our ability to continue as a going concern. If we cannot continue as a viable entity, our stockholders would likely lose most or all of their investment in us.

If we are unable to generate sustainable operating profit and sufficient cash flows, then our future success will depend on our ability to raise capital. We are seeking additional financing and evaluating financing alternatives in order to meet our cash requirements for the next 12 months. We cannot be certain that raising additional capital, whether through selling additional debt or equity securities or obtaining a line of credit or other loan, will be available to us or, if available, will be on terms acceptable to us. If we issue additional securities to raise funds, these securities may have rights, preferences, or privileges senior to those of our common stock, and our current stockholders may experience dilution. If we are unable to obtain funds when needed or on acceptable terms, we may be required to curtail our current product development programs, cut operating costs, forego future development and other opportunities or even terminate our operations.

34

We have a history of losses, and we will need to raise additional capital.

We recorded net losses of approximately $17.8 million and $10.9 million for the nine months ended September 30, 2022 and year ended December 31, 2021, respectively. These and prior-year losses have resulted in significant negative cash flows. To remain competitive and expand our product offerings to customers, we will need to increase revenues substantially beyond levels that we have attained in the past in order to generate sustainable operating profit and sufficient cash flows to continue doing business without raising additional capital from time to time. Given our history of fluctuating revenues and operating losses, and the challenges we face in securing customers for our products, we cannot be certain that we will be able to achieve and maintain profitability on either a quarterly or annual basis in the future. As a result, we will need to raise additional capital to meet our cash requirements for the next 12 months, which may or may not be available to us at all or only on unfavorable terms.

We have significant accounts receivable from a significant customer and collectability is uncertain.

As of September 30, 2022, we had outstanding accounts receivable of $1.6 million, which included $0.7 million collectible from WeLink, a customer that represented 28% of our revenue for the nine months ended September 30, 2022. During the three months ended September 30, 2022, we had $1.1 million of product shipments to WeLink for which the revenue recognition criteria had not been met. Accordingly, we deferred the cost of net revenue of $0.6 million associated with these shipments. Historically, we have collected all amounts due from WeLink, although generally not within contractual payment terms. As of September 30, 2022, we determined that an allowance for doubtful accounts of $0.7 million was warranted on certain outstanding receivables from WeLink due to the collection delays. The longer collection times have negatively impacted our liquidity and working capital. No assurances can be given that we will be able to collect the receivables from WeLink in a timely manner, if at all. Recognition of additional bad debt expense, further delays in collecting accounts receivable or our inability to recognize the deferred cost of net revenues could have a material adverse effect on our financial condition, cash flows and results of operations

The invasion of Ukraine by Russia could negatively impact our business.

Russia’s recent military invasion of Ukraine has led to, and may lead to, additional sanctions being levied by the United States, European Union and other countries against Russia. Russia’s military invasion and the resulting sanctions have had an adverse effect on global markets. We cannot predict the progress or outcome of the situation in Ukraine, as the conflict and governmental reactions are rapidly developing and beyond our control. Prolonged unrest, intensified military activities, or more extensive sanctions impacting the region could have a material adverse effect on the global economy, and such effect could in turn have a material adverse effect on the operations, results of operations, financial condition, liquidity and business outlook of our business.

Sustained inflation could have a material adverse effect on our business, financial condition, results of operations and liquidity.

Inflation rates in the markets in which we operate have increased and may continue to rise. Inflation over the last several months has led us to experience higher costs, including higher labor costs, wafer and other costs for materials from suppliers, and transportation costs. Our suppliers have raised their prices and may continue to raise prices, and, although we have made minimal price increases thus far, in the competitive markets in which we operate, we may not be able to make corresponding price increases to preserve our gross margins and profitability. In addition, inflationary pressures could cause customers to delay or reduce purchases of our products or delay payments to us. If inflation rates continue to rise or remain elevated for a sustained period of time, they could have a material adverse effect on our business, financial condition, results of operations and liquidity.

If our goodwill or intangible assets become impaired, we would be required to record a charge to earnings.

We review our goodwill and intangible assets for impairment when events or changes in circumstances, such as a decline in our stock price and/or market capitalization, indicate the carrying value may not be recoverable. We test goodwill for impairment at least annually. If our goodwill or intangible assets are deemed to be impaired, an impairment loss equal to the amount by which the carrying amount exceeds the fair value of the assets would be recognized. We would be required to record an impairment charge in our financial statements during the period in which any impairment of our goodwill or intangible assets is determined, which would negatively affect our results of operations.

35

ITEM 6. Exhibits

(a) | Exhibits |
| 10.1*+ | Technology License and Patent Assignment Agreement By and Between Intel Corporation and Peraso Inc. dated August 5, 2022
| 31.1* | Rule 13a-14 certification
| 31.2* | Rule 13a-14 certification
| 32.1** | Section 1350 certifications
| 101* | The following financial information from Peraso Inc.’s quarterly report on Form 10-Q for the period ended September 30, 2022, filed with the SEC on November 14, 2022, formatted in Inline Extensible Business Reporting Language (Inline XBRL): (i) the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and nine months ended September 30, 2022 and 2021, (ii) the Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021, (iii) the Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the three and nine months ended September 30, 2022 and 2021, (iv) the Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2022 and 2021, and (v) Notes to Condensed Consolidated Financial Statements.
| 104* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

*Filed herewith.

+ Certain schedules, exhibits and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish copies of such omitted materials supplementally upon request by the SEC.

**Furnished herewith.

36

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: November 14, 2022 |  | PERASO INC.
| By: | /s/ Ronald Glibbery
|  | Ronald Glibbery
|  | Chief Executive Officer (Principal Executive Officer)
| By: | /s/ James W. Sullivan
|  | James W. Sullivan
|  | Chief Financial Officer
|  | (Principal Financial and Accounting Officer)

37